Lasofoxifene treatment of breast cancer

ABSTRACT

The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.

1. CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Application No. 17/045,969, filed Oct. 7, 2020, which is the U.S. National Stage of International Application No. PCT/US2019/026669 filed Apr. 9, 2019, which claims the benefit of U.S. Provisional Application Nos.: 62/655,694, filed Apr. 10, 2018; and 62/678,710, filed May 31, 2018, each of which is hereby incorporated by reference in its entirety.

2. SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted via Patent Center and is hereby incorporated by reference in its entirety. Said XML copy, created on Sep. 22, 2022, is named 53713US_sequencelisting, and is 11,369 bytes in size.

3. BACKGROUND OF THE INVENTION

Estrogen receptor positive (ER⁺) breast cancers are a group of breast cancers that express estrogen receptor α (ERα). Approximately 70% of breast cancers are ER⁺ and are, therefore, treated with endocrine therapy. Endocrine therapy has led to significant improvement in outcome of women with ER⁺ breast cancer by lowering the level of estrogen or blocking estrogen signaling. However, its effectiveness is limited by intrinsic and acquired endocrine resistance.

Recent studies have shown evidence for the temporal selection of functional Estrogen Receptor 1 (ESR1) gene mutations as potential drivers of endocrine resistance during the progression of ER⁺ breast cancer. See Jeselsohn et al., Clinical Cancer Research 20(7): 1757-1767 (2014). The mutations in ESR1, the gene encoding ERα, change the conformation of the ERα protein, increase its interaction with its co-activators, promote an active form of the receptor in absence of hormone, and assist tumor cells in evading hormonal treatment. See Thomas and Gustafsson, Trends in Endocrinology and Metabolism 26(9): 467-476 (2015).

There thus remains a need to develop new therapeutic strategies that are effective to treat tumors harboring mutations in ESR1, and that can therefore be used to treat breast cancer patients who have developed endocrine resistance or who are at risk of developing endocrine resistance.

4. SUMMARY OF THE INVENTION

We engineered ERα expression constructs to express four ESR1 mutations in the ligand binding domain (LBD) of the ERα protein, Y537S, Y537N, Y537C, and D538G, and introduced these expression constructs into cells in culture. These mutations are found in ER⁺ metastatic breast cancer patients who have been treated with endocrine therapy. See Jeselsohn et al., Nature Reviews Clinical Oncology 12(10): 573-583 (2015); Jeselsohn et al., Clinical Cancer Research 20(7): 1757-1767 (2014); Robinson et al., Nature Genetics 45(12): 1446-1451(2013); Thomas and Gustafsson, Trends in Endocrinology and Metabolism 26(9): 467-476 (2015); and Toy et al., Nature Genetics 45(12): 1439-1445 (2013).

Using an estrogen receptor-responsive reporter construct, we confirmed in an ovarian cell line and in a breast cancer cell line that all mutants are constitutively active as compared to wild type ERα. We then treated the cells with lasofoxifene, a selective ER modulator (SERM), and found that lasofoxifene effectively inhibited the transcriptional activity of the ERα LBD mutants in a dose-response manner, at concentrations that are clinically achievable.

In a second series of experiments, we confirmed that lasofoxifene is able to reduce viability of the breast cancer cell line MCF7 stably transfected with either the Y537S or D538G ESR1 mutant receptor, at clinically achievable concentrations.

Experiments in mouse models injected with breast cancer cells expressing D538G and Y537S mutant ERα indicated that lasofoxifene inhibits tumor growth and metastasis of breast cancer in vivo. Lasofoxifene at doses of 5 mg/kg and 10 mg/kg is more effective than fulvestrant in reducing tumor growth and metastasis.

The combination of lasofoxifene and palbociclib is more effective than the combination of fulvestrant and palbociclib in inhibiting tumor growth in the mouse model injected with breast cancer cells expressing Y537S mutant ERα.

We have determined for the first time the x-ray crystal structure of ERα Y537S mutant in the antagonist conformation. The loop between helix 11 and helix 12 is absent in the crystal structure of the lasofoxifene-bound ERα Y537S mutant LBD, which leads to the inactivation of the constitutively active Y537S mutant ERα receptor.

Accordingly, in a first aspect, a method of treating locally advanced or metastatic breast cancer in women is presented. The method comprises selecting for treatment a patient who has been diagnosed with estrogen receptor positive (ER⁺) locally advanced or metastatic breast cancer, and administering to the selected patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

In various embodiments, the selected patient has previously been treated with one or more lines of endocrine therapy. In certain embodiments, the patient has previously been treated with a plurality of lines of endocrine therapy.

In some embodiments, the endocrine therapy that the patient has previously been treated with is a selective ER modulator (SERM). In certain embodiments, the SERM is tamoxifen, raloxifene, bazedoxifene, toremifene, or ospemifene.

In some embodiments, the endocrine therapy that the patient has previously been treated with is a selective ER degrader (SERD). In certain embodiments, the SERD is fulvestrant, RAD1901, ARN-810 (GDC-0810), or AZD9496.

In some embodiments, the endocrine therapy that the patient has previously been treated with is an aromatase inhibitor. In certain embodiments, the aromatase inhibitor is exemestane (Aromasin^(®)), letrozole (Femara^(®)), or anastrozole (Arimidex^(®)).

In some embodiments, the patient has disease progression after endocrine therapy. In some embodiments, the patient is resistant to endocrine therapy.

In various embodiments, the patient’s cancer has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene. In some embodiments, the patient has previously been determined to have at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene. In certain embodiments, the method further comprises the earlier step of: determining that the patient has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene.

In some embodiments, the at least one of gain of function missense mutation is in any one of amino acids D538, Y537, L536, P535, V534, S463, V392, or E380.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid D538. In some preferred embodiments the mutation is D538G.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid Y537. In some embodiments, the mutation is Y537S, Y537N, Y537C, or Y537Q. In some preferred embodiments, the mutation is Y537C.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid L536. In some embodiments, the mutation is L536R or L536Q.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid P535. In some embodiments, the mutation is P535H.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid V534. In some embodiments, the mutation is V534E.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid S463. In some embodiments, the mutation is S463P.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid V392. In some embodiments, the mutation is V392I.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid E380. In some embodiments, the mutation is E380Q.

In some embodiments, the serum estradiol level of the patient is at least 0.35 ng/dL. In some embodiments, the serum estradiol level of the patient is about 0.30 ng/dL to about 0.35 ng/dL. In some embodiments, the serum estradiol level of the patient is about 0.25 ng/dL to about 0.30 ng/dL.

In various embodiments, lasofoxifene is administered to the selected ER⁺ locally advanced or metastatic breast cancer patient as lasofoxifene tartrate. In various embodiments, lasofoxifene is administered by oral, intravenous, transdermal, vaginal topical, or vaginal ring administration. In certain embodiments, lasofoxifene is administered by oral administration. In some of these embodiments, lasofoxifene is administered at about 0.5 mg/day per os (p.o.) to about 10 mg/day per os. In certain embodiments, lasofoxifene is administered at about 0.5 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os. In certain embodiments, lasofoxifene is administered at about 5 mg/day per os. In various embodiments, lasofoxifene is administered once every day, once every two days, once every three days, once every four days, once every five days, once every six days, once every week, once every two weeks, once every three weeks, or once every month.

In certain embodiments, the method further comprises treating the patient with at least one additional endocrine therapy. In some embodiments, the patient is treated with the additional endocrine therapy at original doses. In some other embodiments, the patient is treated with the additional endocrine therapy at doses higher than original doses. In certain embodiments, the additional endocrine therapy is treatment with a selective ER modulator (SERM) other than lasofoxifene. In certain embodiments, the additional endocrine therapy is treatment with a selective ER degrader (SERD). In certain embodiments, the additional endocrine therapy is treatment with an aromatase inhibitor.

In various embodiments, the method further comprises administering to the ER⁺ locally advanced or metastatic breast cancer patient an effective amount of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. In certain embodiments, CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib. In some embodiments, the method further comprises administering to the patient an effective amount of mammalian target of rapamycin (mTOR) inhibitor. In certain embodiments, the mTOR inhibitor is Everolimus. In some embodiments, the method further comprises administering to the patient an effective amount of phosphoinositide 3-kinase (PI3K) inhibitor or heat shock protein 90 (HSP90) inhibitor. In some embodiments, the method further comprises administering to the patient an effective amount of human epidermal growth factor receptor 2 (HER2) inhibitor. In certain embodiments, the HER2 inhibitor is trastuzumab (Herceptin^(®)) or ado-trastuzumab emtansine (Kadcyla^(®)). In some embodiments, the method further comprises administering to the patient an effective amount of a histone deacetylase (HDAC) inhibitor. In some of these embodiments, the HDAC inhibitor is vorinostat (Zolinza^(®)), romidepsin (Istodax^(®)), chidamide (Epidaza^(®)), panobinostat (Farydak^(®)), belinostat (Beleodaq^(®), PXD101), valproic acid (Depakote^(®), Depakene^(®), Stavzor^(®)), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetrin, CUDC-101, AR-42, tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat (ACY-1215), or sulforaphane. In some embodiments, the method further comprises administering to the patient an effective amount of a checkpoint inhibitor. In some of these embodiments, the checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). In certain embodiments, the PD-1 antibody is pembrolizumab (Keytruda^(®)) or nivolumab (Opdivo^(®)). In certain embodiments, the CTLA-4 antibody is ipilimumab (Yervoy^(®)). In some embodiments, the method further comprises administering to the patient an effective amount of cancer vaccine.

In some embodiments, the patient is premenopausal. In certain embodiments, the patient has locally advanced or metastatic ER+/HER2- breast cancer. In some of these embodiments, the patient has progressed on her first hormonal treatment while on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.

In some embodiments, the patient is perimenopausal. In certain embodiments, the patient has locally advanced or metastatic ER+/HER2- breast cancer. In some of these embodiments, the patient has progressed on her first hormonal treatment while on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.

In some embodiments, the patient is postmenopausal. In certain embodiments, the patient has locally advanced or metastatic ER+/HER2- breast cancer. In some of these embodiments, the patient has progressed on her first hormonal treatment while on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.

In another aspect, a method of treating primary breast cancer in women is presented. The method comprises selecting for treatment a patient who has been diagnosed with estrogen receptor positive (ER⁺) primary breast cancer, and administering to the selected patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

In various embodiments, lasofoxifene is administered to the selected ER⁺ primary breast cancer patient as lasofoxifene tartrate. In some embodiments, lasofoxifene is administered by oral, intravenous, transdermal, vaginal topical, or vaginal ring administration. In certain embodiments, lasofoxifene is administered by oral administration. In some of these embodiments, lasofoxifene is administered at about 0.5 mg/day per os to about 10 mg/day per os. In certain embodiments, lasofoxifene is administered at about 0.5 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os. In certain embodiments, lasofoxifene is administered at about 5 mg/day per os. In various embodiments, lasofoxifene is administered once every day, once every two days, once every three days, once every four days, once every five days, once every six days, once every week, once every two weeks, once every three weeks, or once every month.

In various embodiments, the method of treating ER⁺ primary breast cancer further comprises treating the patient with at least one additional endocrine therapy. In some embodiments, the patient is treated with the additional endocrine therapy at original doses. In some other embodiments, the patient is treated with the additional endocrine therapy at doses higher than original doses. In certain embodiments, the additional endocrine therapy is treatment with a selective ER modulator (SERM) other than lasofoxifene. In certain embodiments, the additional endocrine therapy is treatment with a selective ER degrader (SERD). In certain embodiments the additional endocrine therapy is treatment with an aromatase inhibitor.

In various embodiments, the method further comprises administering to the ER⁺ primary breast cancer patient an effective amount of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. In certain embodiments, CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib. In some embodiments, the method further comprises administering to the patient an effective amount of mammalian target of rapamycin (mTOR) inhibitor. In certain embodiments, the mTOR inhibitor is Everolimus. In some embodiments, the method further comprises administering to the patient an effective amount of phosphoinositide 3-kinase (PI3K) inhibitor or heat shock protein 90 (HSP90) inhibitor. In some embodiments, the method further comprises administering to the patient an effective amount of human epidermal growth factor receptor 2 (HER2) inhibitor. In certain embodiments, the HER2 inhibitor is trastuzumab (Herceptin^(®)) or ado-trastuzumab emtansine (Kadcyla^(®)). In some embodiments, the method further comprises administering to the patient an effective amount of a histone deacetylase (HDAC) inhibitor. In some of these embodiments, the HDAC inhibitor is vorinostat (Zolinza^(®)), romidepsin (Istodax^(®)), chidamide (Epidaza^(®)), panobinostat (Farydak®), belinostat (Beleodaq^(®), PXD101), valproic acid (Depakote^(®), Depakene^(®), Stavzor^(®)), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetrin, CUDC-101, AR-42, tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat (ACY-1215), or sulforaphane. In some embodiments, the method further comprises administering to the patient an effective amount of a checkpoint inhibitor. In some of these embodiments, the checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). In certain embodiments, the PD-1 antibody is pembrolizumab (Keytruda^(®)) or nivolumab (Opdivo^(®)). In certain embodiments, the CTLA-4 antibody is ipilimumab (Yervoy^(®)). In some embodiments, the method further comprises administering to the patient an effective amount of cancer vaccine.

In certain embodiments, the patient is premenopausal. In certain embodiments, the patient is perimenopausal. In certain embodiments, the patient is postmenopausal.

In another aspect, a method of adjuvant therapy for estrogen receptor positive (ER+) breast cancer is presented. The method comprises administering to a patient who has received primary treatment for ER+ breast cancer an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof, in combination with an aromatase inhibitor.

In some embodiments, lasofoxifene is administered continuously during the administration of the aromatase inhibitor. In some embodiments, lasofoxifene is administered cyclically during the administration of the aromatase inhibitor. In certain embodiments, the dosing regimen of lasofoxifene is different from the dosing regimen of the aromatase inhibitor.

In various embodiments, lasofoxifene is administered as lasofoxifene tartrate as adjuvant therapy in combination with an aromatase inhibitor. In some embodiments, the aromatase inhibitor is exemestane (Aromasin^(®)), letrozole (Femara^(®)), or anastrozole (Arimidex^(®)).In some embodiments, lasofoxifene is administered by oral, intravenous, transdermal, vaginal topical, or vaginal ring administration. In certain embodiments, lasofoxifene is administered by oral administration. In some of these embodiments, lasofoxifene is administered at about 0.5 mg/day per os to about 10 mg/day per os. In certain embodiments, lasofoxifene is administered at about 0.5 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os. In certain embodiments, lasofoxifene is administered at about 5 mg/day per os. In various embodiments, lasofoxifene is administered once every day, once every two days, once every three days, once every four days, once every five days, once every six days, once every week, once every two weeks, once every three weeks, or once every month.

In various embodiments, the method of adjuvant therapy for estrogen receptor positive (ER+) breast cancer further comprises treating the patient with at least one additional endocrine therapy. In certain embodiments, the additional endocrine therapy is treatment with a selective ER degrader (SERD).

In various embodiments, the method of adjuvant therapy for estrogen receptor positive (ER+) breast cancer further comprises administering to the patient an effective amount of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. In certain embodiments, CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib. In some embodiments, the method further comprises administering to the patient an effective amount of mammalian target of rapamycin (mTOR) inhibitor. In certain embodiments, the mTOR inhibitor is Everolimus. In some embodiments, the method further comprises administering to the patient an effective amount of phosphoinositide 3-kinase (PI3K) inhibitor or heat shock protein 90 (HSP90) inhibitor. In some embodiments, the method further comprises administering to the patient an effective amount of human epidermal growth factor receptor 2 (HER2) inhibitor. In certain embodiments, the HER2 inhibitor is trastuzumab (Herceptin^(®)) or ado-trastuzumab emtansine (Kadcyla^(®)). In some embodiments, the method further comprises administering to the patient an effective amount of a histone deacetylase (HDAC) inhibitor. In some of these embodiments, the HDAC inhibitor is vorinostat (Zolinza^(®)), romidepsin (Istodax^(®)), chidamide (Epidaza^(®)), panobinostat (Farydak^(®)), belinostat (Beleodaq^(®), PXD101), valproic acid (Depakote^(®), Depakene^(®),Stavzor^(®)), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetrin, CUDC-101, AR-42, tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat (ACY-1215), or sulforaphane. In some embodiments, the method further comprises administering to the patient an effective amount of a checkpoint inhibitor. In some of these embodiments, the checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). In certain embodiments, the PD-1 antibody is pembrolizumab (Keytruda^(®)) or nivolumab (Opdivo^(®)). In certain embodiments, the CTLA-4 antibody is ipilimumab (Yervoy^(®)). In some embodiments, the method further comprises administering to the patient an effective amount of cancer vaccine.

In some embodiments, lasofoxifene is administered in an amount and on a schedule sufficient to improve bone mass. In some embodiments, lasofoxifene is administered in an amount and on a schedule sufficient to improve symptoms of VVA.

In certain embodiments, the patient is premenopausal. In certain embodiments, the patient is perimenopausal. In certain embodiments, the patient is postmenopausal.

In another aspect, a method of treating cancers other than breast cancer in women is presented. The method comprises selecting for treatment a patient who has been diagnosed with estrogen receptor positive (ER⁺) cancer, other than breast cancer, and has at least one gain of function mutations in the Estrogen Receptor 1 (ESR1) gene, and administering to the selected patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. In some embodiments, the patient has been diagnosed with ER⁺ ovarian cancer. In some other embodiments, the patient has been diagnosed with ER⁺ lung cancer.

In various embodiments, lasofoxifene is administered to the selected patient with ER⁺ cancer, other than breast cancer, as lasofoxifene tartrate. In some embodiments, lasofoxifene is administered by oral, intravenous, transdermal, vaginal topical, or vaginal ring administration. In certain embodiments, lasofoxifene is administered by oral administration. In some of these embodiments, lasofoxifene is administered at about 0.5 mg/day per os to about 10 mg/day per os. In certain embodiments, lasofoxifene is administered at about 0.5 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os. In certain embodiments, lasofoxifene is administered at about 5 mg/day per os. In various embodiments, lasofoxifene is administered once every day, once every two days, once every three days, once every four days, once every five days, once every six days, once every week, once every two weeks, once every three weeks, or once every month.

In various embodiments, the method of treating ER⁺ cancer, other than breast cancer, further comprises treating the patient with at least one additional endocrine therapy. In some embodiments, the patient is treated with the additional endocrine therapy at original doses. In some other embodiments, the patient is treated with the additional endocrine therapy at doses higher than original doses. In certain embodiments, the additional endocrine therapy is treatment with a selective ER modulator (SERM) other than lasofoxifene. In certain embodiments, the additional endocrine therapy is treatment with a selective ER degrader (SERD). In certain embodiments the additional endocrine therapy is treatment with an aromatase inhibitor.

In various embodiments, the method further comprises administering to the patient with ER⁺ cancer, other than breast cancer, an effective amount of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. In certain embodiments, CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib. In some embodiments, the method further comprises administering to the patient an effective amount of mammalian target of rapamycin (mTOR) inhibitor. In certain embodiments, the mTOR inhibitor is Everolimus. In some embodiments, the method further comprises administering to the patient an effective amount of phosphoinositide 3-kinase (PI3K) inhibitor or heat shock protein 90 (HSP90) inhibitor. In some embodiments, the method further comprises administering to the patient an effective amount of human epidermal growth factor receptor 2 (HER2) inhibitor. In certain embodiments, the HER2 inhibitor is trastuzumab (Herceptin^(®)) or ado-trastuzumab emtansine (Kadcyla^(®)). In some embodiments, the method further comprises administering to the patient an effective amount of a histone deacetylase (HDAC) inhibitor. In some of these embodiments, the HDAC inhibitor is vorinostat (Zolinza^(®)), romidepsin (Istodax^(®)), chidamide (Epidaza^(®)), panobinostat (Farydak^(®)), belinostat (Beleodaq^(®), PXD101), valproic acid (Depakote^(®), Depakene^(®), Stavzor^(®)), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetrin, CUDC-101, AR-42, tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat (ACY-1215), or sulforaphane. In some embodiments, the method further comprises administering to the patient an effective amount of a checkpoint inhibitor. In some of these embodiments, the checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). In certain embodiments, the PD-1 antibody is pembrolizumab (Keytruda^(®)) or nivolumab (Opdivo^(®)). In certain embodiments, the CTLA-4 antibody is ipilimumab (Yervoy®). In some embodiments, the method further comprises administering to the patient an effective amount of cancer vaccine.

In certain embodiments, the patient is premenopausal. In certain embodiments, the patient is perimenopausal. In certain embodiments, the patient is postmenopausal.

In another aspect, a method of treating a female patient suffering from breast cancer who is at risk of acquiring a gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene is presented. The method comprises administering to the female patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

In another aspect, a method of treating a female patient suffering from breast cancer who is at risk of acquiring resistance to endocrine therapy is presented. The endocrine therapy is optionally (i) selective ER modulator (SERM) therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase inhibitor (AI) therapy, or (iv) any combination of (i), (ii) and/or (iii). The method comprises administering to the female patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

In some embodiments, the patient has primary breast cancer. In some of these embodiments, the primary breast cancer is locally advanced.

In various embodiments, the patient has been treated with endocrine therapy, optionally wherein the endocrine therapy is (i) selective ER modulator (SERM) therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase inhibitor (AI) therapy, or (iv) any combination of (i), (ii) and/or (iii).

In another aspect, a method of treating a female patient suffering from estrogen receptor positive (ER+) primary breast cancer is presented. The method comprises administering to a female patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

In some embodiments, the patient is at risk of acquiring resistance to endocrine therapy, optionally wherein the endocrine therapy is (i) selective ER modulator (SERM) therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase inhibitor (AI) therapy, or (iv) any combination of (i), (ii) and/or (iii).

In certain embodiments, the primary breast cancer is locally advanced.

In some embodiments, the patient has been treated with endocrine therapy, optionally wherein the endocrine therapy is (i) selective ER modulator (SERM) therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase inhibitor (AI) therapy, or (iv) any combination of (i), (ii) and/or (iii).

In another aspect, a method of treating a female patient suffering from estrogen receptor positive (ER+) locally advanced or metastatic breast cancer is presented. The method comprises administering to a female patient an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

In various embodiments, the selected patient has previously been treated with one or more lines of endocrine therapy. In certain embodiments, the patient has previously been treated with a plurality of lines of endocrine therapy.

In some embodiments, the endocrine therapy that the patient has previously been treated with is a selective ER modulator (SERM). In certain embodiments, the SERM is tamoxifen, raloxifene, bazedoxifene, toremifene, or ospemifene.

In some embodiments, the endocrine therapy that the patient has previously been treated with is a selective ER degrader (SERD). In certain embodiments, the SERD is fulvestrant, RAD1901, ARN-810 (GDC-0810), or AZD9496.

In some embodiments, the endocrine therapy that the patient has previously been treated with is an aromatase inhibitor. In certain embodiments, the aromatase inhibitor is exemestane (Aromasin^(®)), letrozole (Femara^(®)), or anastrozole (Arimidex^(®)).

In some embodiments, the patient has disease progression after endocrine therapy. In some embodiments, the patient is resistant to endocrine therapy.

In various embodiments, the patient’s cancer has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene. In some embodiments, the patient has previously been determined to have at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene. In certain embodiments, the method further comprises the earlier step of: determining that the patient has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene.

In some embodiments, the at least one of gain of function missense mutation is in any one of amino acids D538, Y537, L536, P535, V534, S463, V392, or E380.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid D538. In some preferred embodiments the mutation is D538G.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid Y537. In some embodiments, the mutation is Y537S, Y537N, Y537C, or Y537Q. In some preferred embodiments, the mutation is Y537C.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid L536. In some embodiments, the mutation is L536R or L536Q.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid P535. In some embodiments, the mutation is P535H.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid V534. In some embodiments, the mutation is V534E.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid S463. In some embodiments, the mutation is S463P.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid V392. In some embodiments, the mutation is V392I.

In certain embodiments, the at least one gain of function missense mutation is in the amino acid E380. In some embodiments, the mutation is E380Q.

In various embodiments, lasofoxifene is administered to the selected ER⁺ locally advanced or metastatic breast cancer patient as lasofoxifene tartrate. In various embodiments, lasofoxifene is administered by oral, intravenous, transdermal, vaginal topical, or vaginal ring administration. In certain embodiments, lasofoxifene is administered by oral administration. In some of these embodiments, lasofoxifene is administered at about 0.5 mg/day per os (p.o.) to about 10 mg/day per os. In certain embodiments, lasofoxifene is administered at about 0.5 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os to about 5 mg/day per os. In certain embodiments, lasofoxifene is administered at about 1 mg/day per os. In certain embodiments, lasofoxifene is administered at about 5 mg/day per os. In various embodiments, lasofoxifene is administered once every day, once every two days, once every three days, once every four days, once every five days, once every six days, once every week, once every two weeks, once every three weeks, or once every month.

In certain embodiments, the method further comprises treating the patient with at least one additional endocrine therapy. In some embodiments, the patient is treated with the additional endocrine therapy at original doses. In some other embodiments, the patient is treated with the additional endocrine therapy at doses higher than original doses. In certain embodiments, the additional endocrine therapy is treatment with a selective ER modulator (SERM) other than lasofoxifene. In certain embodiments, the additional endocrine therapy is treatment with a selective ER degrader (SERD). In certain embodiments, the additional endocrine therapy is treatment with an aromatase inhibitor.

In various embodiments, the method further comprises administering to the ER⁺ locally advanced or metastatic breast cancer patient an effective amount of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. In certain embodiments, CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib. In some embodiments, the method further comprises administering to the patient an effective amount of mammalian target of rapamycin (mTOR) inhibitor. In certain embodiments, the mTOR inhibitor is Everolimus. In some embodiments, the method further comprises administering to the patient an effective amount of phosphoinositide 3-kinase (PI3K) inhibitor or heat shock protein 90 (HSP90) inhibitor. In some embodiments, the method further comprises administering to the patient an effective amount of human epidermal growth factor receptor 2 (HER2) inhibitor. In certain embodiments, the HER2 inhibitor is trastuzumab (Herceptin®) or ado-trastuzumab emtansine (Kadcyla^(®)). In some embodiments, the method further comprises administering to the patient an effective amount of a histone deacetylase (HDAC) inhibitor. In some of these embodiments, the HDAC inhibitor is vorinostat (Zolinza^(®)), romidepsin (Istodax^(®)), chidamide (Epidaza^(®)), panobinostat (Farydak^(®)), belinostat (Beleodaq^(®), PXD101), valproic acid (Depakote^(®), Depakene^(®), Stavzor^(®)), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetrin, CUDC-101, AR-42, tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat (ACY-1215), or sulforaphane. In some embodiments, the method further comprises administering to the patient an effective amount of a checkpoint inhibitor. In some of these embodiments, the checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). In certain embodiments, the PD-1 antibody is pembrolizumab (Keytruda^(®)) or nivolumab (Opdivo^(®)). In certain embodiments, the CTLA-4 antibody is ipilimumab (Yervoy^(®)). In some embodiments, the method further comprises administering to the patient an effective amount of cancer vaccine.

In some embodiments, the patient is premenopausal. In certain embodiments, the patient has locally advanced or metastatic ER+/HER2- breast cancer. In some of these embodiments, the patient has progressed on her first hormonal treatment while on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.

In some embodiments, the patient is perimenopausal. In certain embodiments, the patient has locally advanced or metastatic ER+/HER2- breast cancer. In some of these embodiments, the patient has progressed on her first hormonal treatment while on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.

In some embodiments, the patient is postmenopausal. In certain embodiments, the patient has locally advanced or metastatic ER+/HER2- breast cancer. In some of these embodiments, the patient has progressed on her first hormonal treatment while on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.

5. BRIEF DESCRIPTION OF THE DRAWINGS

These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description, and accompanying drawings, where:

FIG. 1A and FIG. 1B show the effects of lasofoxifene on ESR1 ligand binding domain (“LBD”) mutations in Caov2 ovarian carcinoma cells, with FIG. 1A demonstrating that the mutant receptors are constitutively active and do not respond to 17-β estradiol (“E2”), and FIG. 1B demonstrating that lasofoxifene inhibits the mutant receptor activity in a dose-response manner.

FIG. 2A and FIG. 2B show the effects of lasofoxifene on ESR1 LBD mutations in SKBR3 breast adenocarcinoma cells, with FIG. 2A demonstrating that the mutant receptors are constitutively active and do not respond to 17-β estradiol (E2), and FIG. 2B demonstrating that lasofoxifene inhibits the mutant receptor activity in a dose-response manner.

FIG. 3A and FIG. 3B show the effects of lasofoxifene on ESR1 LBD mutations in stably transfected MCF7 breast cancer cells, with FIG. 3A demonstrating that lasofoxifene inhibits the Y537S mutant receptor activity with increasing dose titration, and FIG. 3B demonstrating that lasofoxifene inhibits the D538G mutant receptor activity with increasing dose titration.

FIG. 4 shows the experimental design for testing the efficacy of lasofoxifene in a mammary intraductal (MIND) xenograft model injected with MCF7 cell variants.

FIGS. 5A, 5B, 5C, 5D and 5E show the bioluminescence images of mice injected with luciferase reporter-labeled MCF7 wild type cells (MCF7 WT) 70 days after treatment, with FIG. 5A showing mice treated with vehicle control, FIG. 5B showing mice treated with 1 mg/kg lasofoxifene, FIG. 5C showing mice treated with 5 mg/kg lasofoxifene, FIG. 5D showing mice treated with 10 mg/kg lasofoxifene, and FIG. 5E showing mice treated with fulvestrant.

FIGS. 6A, 6B, 6C, 6D and 6E show the bioluminescence images of mice injected with luciferase reporter-labeled MCF7 Y537S ERα mutant cells (MCF7 Y537S) 70 days after treatment, with FIG. 6A showing mice treated with vehicle control, FIG. 6B showing mice treated with 1 mg/kg lasofoxifene, FIG. 6C showing mice treated with 5 mg/kg lasofoxifene, FIG. 6D showing mice treated with 10 mg/kg lasofoxifene, and FIG. 6E showing mice treated with fulvestrant.

FIGS. 7A, 7B, 7C, 7D and 7E show the bioluminescence images of mice injected with luciferase reporter-labeled MCF7 D538G ERα mutant cells (MCF7 D538G) 70 days after treatment, with FIG. 7A showing mice treated with vehicle control, FIG. 7B showing mice treated with1 mg/kg lasofoxifene, FIG. 7C showing mice treated with 5 mg/kg lasofoxifene, FIG. 7D showing mice treated with 10 mg/kg lasofoxifene, and FIG. 7E showing mice treated with fulvestrant.

FIGS. 8A, 8B, and 8C show the total flux measured in mice injected with luciferase reporter-labeled MCF7 cells after treatment with vehicle control, lasofoxifene (1 mg/kg, 5 mg/kg, or 10 mg/kg), or fulvestrant, with FIG. 8A showing the total flux measured in MCF7 WT mice, FIG. 8B showing the total flux measured in MCF7 Y537S mice, and FIG. 8C showing the total flux measured in MCF7 D538G mice.

FIGS. 9A, 9B, and 9C show the total flux measured in MCF7 WT mice after treatment with vehicle control, lasofoxifene (10 mg/kg), or fulvestrant, with FIG. 9A showing the total flux measured on the right side of the mice, FIG. 9B showing the total flux measured on the belly of the mice, and FIG. 9C showing the total flux measured on the left side of the mice.

FIGS. 10A, 10B, and 10C show the total flux measured in MCF7 Y537S mice after treatment with vehicle control, lasofoxifene (10 mg/kg), or fulvestrant, with FIG. 10A showing the total flux measured on the right side of the mice, FIG. 10B showing the total flux measured on the belly of the mice, and FIG. 10C showing the total flux measured on the left side of the mice.

FIGS. 11A, 11B, and 11C show the total flux measured in MCF7 D538G mice after treatment with vehicle control, lasofoxifene (10 mg/kg), or fulvestrant, with FIG. 11A showing the total flux measured on the right side of the mice, FIG. 11B showing the total flux measured on the belly of the mice, and FIG. 11C showing the total flux measured on the left side of the mice.

FIGS. 12A and 12B show the tumor weight of MCF7 WT, MCF7 Y537S, and MCF7 D538G mice after treatment with vehicle control, lasofoxifene (1 mg/kg, 5 mg/kg, or 10 mg/kg), or fulvestrant, with FIG. 12A showing the tumor weight in whisker plot and FIG. 12B showing the tumor weight in filled histogram.

FIG. 13 shows the metastasis to liver of MCF7 WT, MCF7 Y537S, and MCF7 D538G cells introduced into mouse mammary glands by intraductal injection, following treatment with vehicle control or lasofoxifene (1 mg/kg, 5 mg/kg, or 10 mg/kg). The liver sections were stained with hematoxylin and eosin (H&E).

FIG. 14 shows the metastasis to liver of MCF7 Y537S cells introduced into mouse mammary glands by intraductal injection, following treatment with vehicle control, lasofoxifene (1 mg/kg, 5 mg/kg, or 10 mg/kg) or fulvestrant. The liver sections were stained with H&E.

FIG. 15 shows the percentage area of liver occupied by metastases of MCF7 Y537S and MCF7 D538G mice after treatment with vehicle control, lasofoxifene (1 mg/kg, 5 mg/kg, or 10 mg/kg), or fulvestrant.

FIG. 16 shows the metastasis to lung of MCF7 WT cells introduced into mouse mammary glands by intraductal injection, following treatment with vehicle control or lasofoxifene (1 mg/kg, 5 mg/kg, or 10 mg/kg). The lung sections were stained with H&E.

FIG. 17 shows the metastasis to lung of MCF7 Y537S cells introduced into mouse mammary glands by intraductal injection, following treatment with vehicle control, lasofoxifene (1 mg/kg, 5 mg/kg, or 10 mg/kg), or fulvestrant. The lung sections were stained with H&E.

FIG. 18 shows the metastasis to lung of MCF7 D538G cells introduced into mouse mammary glands by intraductal injection, following treatment with vehicle control or lasofoxifene (1 mg/kg, 5 mg/kg, or 10 mg/kg). The lung sections were stained with H&E.

FIG. 19 plots the number of lung metastases of MCF7 Y537S cells introduced into mouse mammary glands by intraductal injection following treatment with vehicle control, lasofoxifene (1 mg/kg, 5 mg/kg, or 10 mg/kg), or fulvestrant.

FIG. 20 shows the experimental design for testing the efficacy of combination therapies in a mammary intraductal (MIND) xenograft model injected with MCF7 cell variants.

FIGS. 21A and 21B show the total flux measured on the right side and left side of mice injected with luciferase reporter-labeled MCF7 cells after treatment with vehicle control, fulvestrant, lasofoxifene, palbociclib, fulvestrant plus palbociclib, or lasofoxifene plus palbociclib, with FIG. 21A showing the total flux measured in MCF7 WT mice and FIG. 21B showing the total flux measured in MCF7 Y537S mice.

FIGS. 22A and 22B show the tumor volume in mice injected with luciferase reporter-labeled MCF7 cells after treatment with vehicle control, fulvestrant, lasofoxifene, palbociclib, fulvestrant plus palbociclib, or lasofoxifene plus palbociclib at day 36 and day 43, with FIG. 22A showing the tumor volume in MCF7 WT mice and FIG. 22B showing the tumor volume in MCF7 Y537S mice.

FIGS. 23A and 23B present the crystal structure of lasofoxifene-bound human estrogen receptor ligand binding domain (ER LBD), with FIG. 23A presenting the crystal structure of lasofoxifene-bound wild-type ER LBD and FIG. 23B presenting the crystal structure of lasofoxifene-bound Y537S mutant ER LBD.

FIG. 24 presents the merged crystal structures of lasofoxifene-bound wild-type ER LBD and lasofoxifene-bound Y537S mutant ER LBD.

FIG. 25 provides a schematic showing conformational states of the wild-type ER unbound to estrogen, the wild-type ER bound to estrogen, mutant ER with a ligand binding domain gain of function mutation, and the mutant ER bound by lasofoxifene.

FIG. 26 presents the design of the phase 2 clinical study.

6. DETAILED DESCRIPTION OF THE INVENTION

Endocrine therapy is often used for treatment and prevention of ER⁺ breast cancers. Different types of endocrine therapy include selective ER modulators (SERMs), such as tamoxifen; selective ER degraders (SERDs), such as fulvestrant; and aromatase inhibitors (AIs). Although endocrine therapy has led to a significant improvement in outcome for women with ER⁺ breast cancer, its effectiveness is limited by intrinsic and acquired endocrine resistance. Recent studies on the mechanism of endocrine resistance have demonstrated that in some cases Estrogen Receptor 1 (ESR1) gene mutations lead to the conformational change of the ERα protein towards a constitutively active state and result in ligand-independent activity that is relatively resistant to tamoxifen, fulvestrant, and estrogen deprivation. See Jeselsohn et al., Clinical Cancer Research 20(7): 1757-1767 (2014).

Lasofoxifene is a nonsteroidal selective ER modulator (SERM). It has high binding affinity for the estrogen receptor and acts as a tissue-selective estrogen agonist or antagonist. In the double-blind, placebo-controlled, randomized Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene (PEARL) trial, lasofoxifene was found to reduce the risk of osteoporosis. See Cummings et al., The New England Journal of Medicine 326(8): 686-696 (2010). In the PEARL trial, it was also found that lasofoxifene reduced the risk of breast cancer in post-menopausal women with osteoporosis. See LaCroix et al., Journal of the National Cancer Institute 102(22): 1706-1715 (2010). However, the effect of lasofoxifene as a treatment for breast cancer, and its effect on cancers with endocrine resistance, has not previously been determined.

Using cell lines with engineered mutations in the ESR1 gene, we discovered that lasofoxifene inhibits the mutant receptor activity in a dose-responsive manner at concentrations that can be achieved clinically, newly making possible methods of treating ER⁺ locally advanced or metastatic breast cancer, ER⁺ primary breast cancer, and other ER⁺ cancers, including cancers having ESR1 mutations, using lasofoxifene, whose effectiveness is not precluded by endocrine resistance.

6.1. Methods of Treatment

Accordingly, in a first aspect, disclosed herein are methods of treating cancers in women, comprising selecting for treatment a patient who has been diagnosed with estrogen receptor positive (ER⁺) cancer. The selected patient is treated with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

6.1.1. Patient with ER⁺ Cancer

In various embodiments, the patient has been diagnosed with ER⁺ cancer by immunohistochemistry (IHC) performed on a sample of the patient’s cancer. In some embodiments, the patient has been diagnosed with locally advanced or metastatic ER⁺ breast cancer. In some embodiments, the patient has been diagnosed with ER⁺ primary breast cancer. In some embodiments, the patient has been diagnosed with an ER⁺ cancer other than breast cancer. In some of these embodiments, the patient has been diagnosed with ER⁺ ovarian cancer. In some of these embodiments, the patient has been diagnosed with ER⁺ lung cancer.

In some embodiments, cells of the patient’s cancer have acquired a gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene.

In some embodiments, the patient is at risk of acquiring resistance to endocrine therapy. In particular embodiments, the patient is at risk of acquiring resistance to endocrine therapy due to the increased expression of estrogen receptor. In particular embodiments, the patient is at risk of acquiring resistance to endocrine therapy due to the increased expression of co-activators of estrogen receptor. In particular embodiments, the patient is at risk of acquiring resistance to endocrine therapy due to increased phosphorylation level and activity of estrogen receptor and its co-activators. In particular embodiments, the patient is at risk of acquiring resistance to endocrine therapy due to change of tumor microenvironment and other host related factors. In some preferred embodiments, the patient is at risk of acquiring resistance to endocrine therapy due to mutations in the Estrogen Receptor 1 (ESR1) gene.

In some of these embodiments, the endocrine therapy to which the patient is at risk of acquiring resistance is (i) selective ER modulator (SERM) therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase inhibitor therapy (AI), or (iv) any combination of (i), (ii) and/or (iii).

6.1.2. Previous Treatment with Endocrine Therapy

In various embodiments, the ER⁺ cancer patient has previously been treated with one or more lines of endocrine therapy. In certain embodiments, the patient has previously been treated with one line of endocrine therapy. In certain other embodiments, the patient has previously been treated with a plurality of lines of endocrine therapy. In some embodiments, the patient has previously been treated with two lines of endocrine therapy. In some embodiments, the patient has previously been treated with three lines of endocrine therapy. In some embodiments, the patient has previously been treated with four or more lines of endocrine therapy.

In some embodiments, the endocrine therapy that the patient has previously been treated with is a selective ER modulator (SERM). In some embodiments, the selective ER modulator is selected from tamoxifen, raloxifene, bazedoxifene, toremifene, and ospemifene. In certain embodiments, the selective ER modulator is tamoxifen.

In some embodiments, the endocrine therapy that the patient has previously been treated with is a selective ER degrader (SERD). In various embodiments, the selective ER degrader binds to the estrogen receptor and leads to the proteasomal degradation of the receptor. In some embodiments, the selective ER degrader is selected from fulvestrant, RAD1901, ARN-810 (GDC-0810), and AZD9496. In certain embodiments, the selective ER degrader is fulvestrant.

In some embodiments, the endocrine therapy with which the patient has previously been treated is an aromatase inhibitor (AI). In various embodiments, the aromatase inhibitor blocks the production of estrogen. In some embodiments, the aromatase inhibitor is selected from exemestane (Aromasin^(®)), letrozole (Femara^(®)), and anastrozole (Arimidex^(®)).

In some embodiments, the endocrine therapy that the patient has previously been treated with is ovarian suppression. In certain embodiments, ovarian suppression is achieved by oophorectomy. In certain embodiments, ovarian suppression is achieved by administration of a GnRH antagonist.

In certain embodiments, the patient’s cancer has relapsed or progressed after the previous endocrine therapy treatment. In some embodiments, the patient’s cancer has relapsed or progressed after tamoxifen treatment. In some embodiments, the patient’s cancer has relapsed or progressed after fulvestrant treatment. In some embodiments, the patient’s cancer has relapsed or progressed after aromatase inhibitor treatment. In some of these embodiments, the patient’s cancer has relapsed or progressed after multiple lines of endocrine therapy treatment.

In some embodiments, the ER⁺ cancer patient has not been treated previously with endocrine therapy.

In certain embodiments, the patient is resistant to endocrine therapy other than lasofoxifene. In some embodiments, the patient has intrinsic endocrine resistance. In some embodiments, the patient has acquired endocrine resistance. In particular embodiments, the patient is resistant to endocrine therapy due to the increased expression of estrogen receptor. In particular embodiments, the patient is resistant to endocrine therapy due to the increased expression of co-activators of estrogen receptor. In particular embodiments, the patient is resistant to endocrine therapy due to increased phosphorylation level and activity of estrogen receptor and its co-activators. In particular embodiments, the patient is resistant to endocrine therapy due to change of tumor microenvironment and other host related factors. In some preferred embodiments, the patient is resistant to endocrine therapy due to gene mutations in the Estrogen Receptor 1 (ESR1) gene.

In various embodiments, the patient is resistant to clinical doses of one or more SERMs other than lasofoxifene. In some of these embodiments, the patient is resistant to clinical doses of tamoxifen. In various embodiments, the patient is resistant to clinical doses of one or more SERDs. In some of these embodiments, the patient is resistant to clinical doses of fulvestrant. In various embodiments, the patient is resistant to clinical doses of one or more aromatase inhibitors. In various embodiments, the patient is resistant to higher than clinical doses of one or more SERMs other than lasofoxifene. In some of these embodiments, the patient is resistant to higher than clinical doses of tamoxifen. In various embodiments, the patient is resistant to higher than clinical doses of one or more SERDs. In some of these embodiments, the patient is resistant to higher than clinical doses of fulvestrant. In various embodiments, the patient is resistant to higher than clinical doses of one or more aromatase inhibitors.

In certain embodiments, the ER⁺ cancer patient has not been demonstrated to have endocrine resistance. In some of these embodiments, the patient has not been demonstrated to have endocrine resistance due to the limitations of the detection methods.

In some embodiments, lasofoxifene is administered to the ER⁺ cancer patient after completion of cancer treatment. In some of these embodiments, lasofoxifene is administered to the patient to treat occult micrometastasis.

6.1.3. Menopause Status

In some embodiments, the ER⁺ cancer patient is premenopausal. In specific embodiments, the patient is premenopausal and has locally advanced or metastatic ER⁺ cancer. In particular embodiments, the patient is premenopausal and has locally advanced or metastatic ER⁺ breast cancer.

In certain embodiments, the ER⁺ cancer patient is perimenopausal. In specific embodiments, the patient is perimenopausal and has locally advanced or metastatic ER⁺ cancer. In particular embodiments, the patient is perimenopausal and has locally advanced or metastatic ER⁺ breast cancer.

In typical embodiments, the ER⁺ cancer patient is postmenopausal. In specific embodiments, the patient is postmenopausal and has locally advanced or metastatic ER⁺ cancer. In particular embodiments, the patient is postmenopausal and has locally advanced or metastatic ER⁺ breast cancer.

In certain embodiments, lasofoxifene is administered to a premenopausal woman with locally advanced or metastatic ER⁺/HER2⁻ breast cancer. In certain embodiments, lasofoxifene is administered to a premenopausal woman with locally advanced or metastatic ER⁺/HER2⁻ breast cancer who has progressed while on her first hormonal treatment with a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.

In certain embodiments, lasofoxifene is administered to a perimenopausal woman with locally advanced or metastatic ER⁺/HER2⁻ breast cancer. In certain embodiments, lasofoxifene is administered to a perimenopausal woman with locally advanced or metastatic ER⁺/HER2⁻ breast cancer who has progressed while on her first hormonal treatment with a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.

In certain embodiments, lasofoxifene is administered to a postmenopausal woman with locally advanced or metastatic ER⁺/HER2⁻ breast cancer. In certain embodiments, lasofoxifene is administered to a postmenopausal woman with locally advanced or metastatic ER⁺/HER2⁻ breast cancer who has progressed while on her first hormonal treatment with on a non-steroid aromatase inhibitor (AI), fulvestrant, AI in combination with a CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor.

6.1.4. Mutations in ESR1 Gene

In various embodiments, the patient has an ER⁺ cancer, cells of which have at least one mutation in the Estrogen Receptor 1(ESR1) gene, which encodes the Estrogen Receptor a (ERα) protein. In some embodiments, the mutation leads to the ligand-independent activity of the estrogen receptor. In some embodiments, the mutation leads to enhanced ligand stimulated activity of estrogen receptor. In some embodiments, the mutation leads to resistance to endocrine therapy. In some embodiments, the mutation promotes tumor growth. In some embodiments, the mutation enhances metastatic activity of cancer. In some preferred embodiments, the mutation enhances metastatic activity of ER⁺ metastatic breast cancer.

In some embodiments, the mutation arises from a rare and undetectable pre-existing clone. In some embodiments, the mutation is acquired de novo during the course of endocrine therapy treatment. In some preferred embodiments, the mutation is acquired de novo during the course of endocrine therapy treatment of breast cancer. In some embodiments, the mutation is acquired de novo after multiple lines of endocrine therapy treatment. In some embodiments, the mutation is acquired de novo after multiple lines of endocrine therapy treatment of metastatic breast cancer. In various embodiments, the mutant clone expands to become a more dominant clone over the course of successive lines of endocrine therapy.

In some embodiments, the mutation in the ESR1 gene is missense point mutation. In some embodiments, the mutation in the ESR1 gene is truncating mutation. In some embodiments, the mutation in the ESR1 gene is gene amplification. In some embodiments, the mutation in the ESR1 gene is genomic rearrangement.

In some preferred embodiments, the patient has an ER⁺ cancer that has at least one gain of function missense mutation within the ligand binding domain (LBD) of the ESR1 gene. In various embodiments, at least one of the mutations is in an amino acid selected from D538, Y537, L536, P535, V534, S463, V392, and E380. (The amino acids are numbered according to the ESR1 protein with the NCBI accession number NP_000116.2.)

In particular embodiments, the mutation increases the stability of the agonist conformation of Helix 12 of the ERα protein. In some of these embodiments, the mutation increases the binding of the estrogen receptor to its co-activators. In some of these embodiments, the mutation leads to hormone independent activity of estrogen receptor. In some of these embodiments, the mutation leads to resistance to tamoxifen, fulvestrant, and/or aromatase inhibitors.

In certain embodiments, the mutation is in the amino acid D538. In certain preferred embodiments, the mutation is D538G.

In certain embodiments, the mutation is in the amino acid Y537. In some of these embodiments, the mutation is Y537S, Y537N, Y537C, or Y537Q. In certain preferred embodiments, the mutation is Y537C.

In some embodiments, the mutation is in the amino acid L536. In certain embodiments, the mutation is L536R or L536Q.

In some embodiments, the mutation is in the amino acid P535. In certain embodiments, the mutation is P535H.

In some embodiments, the mutation is in the amino acid V534. In certain embodiments, the mutation is V534E.

In some embodiments, the mutation is in the amino acid S463. In certain embodiments, the mutation is S463P.

In some embodiments, the mutation is in the amino acid V392. In certain embodiments, the mutation is V392I.

In some embodiments, the mutation is in the amino acid E380. In certain embodiments, the mutation is E380Q.

6.1.4.1. Detection of the ESR1 Gene Mutations

In various embodiments, the patient has been previously determined to have at least one mutation in the ESR1 gene. Some embodiments of the methods described herein further include the step of detecting the mutations in ESR1 gene.

In some embodiments, massively parallel next generation sequencing (NGS) is used for detecting the estrogen receptor mutations in the patient’s cancer. In certain embodiments, the entire genome is sequenced. In certain embodiments, selected gene panels of cancer-related genes are sequenced. In certain embodiments, all coding exons within a given set of genes are sequenced. In certain embodiments, known “hotspot” regions within a given set of genes are sequenced. However, the inherent error rate of current next generation sequencing techniques is up to 1%, limiting the sensitivity and specificity of detection. In some embodiments, targeted sequencing is used for detecting the presence of the ESR1 mutations. Although targeted sequencing allows deeper sequencing, it is also currently limited by the 1% error rate. In some embodiments, methods with reduced sequencing error rate are used. In a particular embodiment, Safe-Sequencing System (Safe-SeqS) is used, which tags each template molecule to allow for confident identification of rare variants. See Kinde et al., Proceedings of the National Academy of Sciences 108(23): 9530-9535 (2011). In particular embodiments, ultrasensitive Duplex sequencing is used, which independently tags and sequences each of the two strands of a DNA duplex. See Schmitt et al., Proceedings of the National Academy of Sciences 109(36): 14508-14513 (2012). In some embodiments, digital droplet PCR is used, which emulsifies DNA in thousands to millions of droplets to encapsulate single DNA molecules, designed with mutant specific primers. See Vogelstein and Kinzler, Proceedings of the National Academy of Sciences 96(16): 2322-2326 (1999) and Huggett et al., Clinical Chemistry 61(1): 79-88 (2014).

In some embodiments, the detection of the ESR1 mutations takes place at the initial diagnosis. In some embodiments, the detection of the mutations takes place at the time of disease progression, relapse, or recurrence. In some embodiments, the detection of the mutations takes place at the time of disease progression. In some embodiments, the detection of the mutations takes place at the time when the disease is stable.

In some embodiments, one or more tissue specimens are obtained for detection of the mutations. In certain embodiments, the tissue specimen is a tumor biopsy. In certain embodiments, the tissue specimen is a biopsy of metastases. In some other embodiments, liquid biopsies are obtained for detection of the mutations. In certain embodiments, the liquid biopsy is circulating tumor cells (CTCs). In certain other embodiments, the liquid biopsy is cell-free DNA from blood samples.

In specific embodiments, the ESR1 mutations are monitored by circulating tumor DNA (ctDNA) analysis. In some embodiments, the ctDNA analysis is performed throughout the course of treatment. In some of these embodiments, the ctDNA is extracted from patient blood samples. In certain embodiments, the ctDNA is evaluated by digital PCR analysis of the ESR1 mutations.

6.1.5. Estradiol Levels

In various embodiments, the patient selected for treatment based on presence of ESR1 gene mutations is further selected based on serum estradiol level.

In certain embodiments, the serum estradiol level of the patient with the ER⁺ cancer having an ESR1 gene mutation is at least 0.20 ng/dL, such as at least 0.25 ng/dL, at least 0.30 ng/dL, at least 0.35 ng/dL, at least 0.40 ng/dL, at least 0.45 ng/dL, at least 0.50 ng/dL, at least 0.55 ng/dL, at least 0.60 ng/dL, at least 0.65 ng/dL, at least 0.70 ng/dL, at least 0.75 ng/dL, at least 0.80 ng/dL, at least 0.85 ng/dL, at least 0.90 ng/dL, at least 0.95 ng/dL, or at least 1.0 ng/dL.

In certain embodiments, the serum estradiol level of the patient with the ESR1 gene mutation is about 0.20 ng/dL to about 1.0 ng/dL, such as about 0.20 ng/dL to about 0.25 ng/dL, about 0.25 ng/dL to about 0.30 ng/dL, about 0.30 ng/dL to about 0.35 ng/dL, about 0.35 ng/dL to about 0.40 ng/dL, about 0.40 ng/dL to about 0.45 ng/dL, about 0.45 ng/dL to about 0.50 ng/dL, about 0.50 ng/dL to about 0.55 ng/dL, about 0.55 ng/dL to about 0.60 ng/dL, about 0.60 ng/dL to about 0.65 ng/dL, about 0.65 ng/dL to about 0.70 ng/dL, about 0.70 ng/dL to about 0.75 ng/dL, about 0.75 ng/dL to about 0.80 ng/dL, about 0.80 ng/dL to about 0.85 ng/dL, about 0.85 ng/dL to about 0.90 ng/dL, about 0.90 ng/dL to about 0.95 ng/dL, about 0.95 ng/dL to about 1.0 ng/dL.

6.1.6. Adjuvant Treatment

In various embodiments, lasofoxifene is administered to the patient as adjuvant treatment. In certain embodiments, lasofoxifene is administered to the patient as adjuvant treatment alone. In certain other embodiments, lasofoxifene is administered to the patient as adjuvant treatment in combination with other endocrine therapies. In some embodiments, lasofoxifene is administered to the patient after the primary treatment. In some of these embodiments, lasofoxifene is administered to the patient after surgical removal or debulking of the cancer.

In some embodiments, lasofoxifene is administered to the patient as adjuvant therapy in combination with an aromatase inhibitor (AI). In various embodiments, the aromatase inhibitor is exemestane (Aromasin^(®)), letrozole (Femara^(®)), or anastrozole (Arimidex^(®)).

In various embodiments, the aromatase inhibitor predisposes the patient to bone-related toxic effects. In some embodiments, the aromatase inhibitor predisposes the patient to osteoporosis. In some embodiments, the aromatase inhibitor predisposes the patient to bone loss. In some embodiments, the aromatase inhibitor predisposes the patient to bone fractures. In some embodiments, the aromatase inhibitor predisposes the patient to bone pain.

In various embodiments, the aromatase inhibitor predisposes the patient to vulvovaginal atrophy (VVA).

In some embodiments, lasofoxifene is administered continuously during the administration of the aromatase inhibitor. In some other embodiments, lasofoxifene is administered cyclically during the administration of the aromatase inhibitor. In some embodiments, lasofoxifene and the aromatase inhibitor are administered together (simultaneously). In some other embodiments, lasofoxifene and the aromatase inhibitor are administered separately (sequentially).

In certain embodiments, the dosing regimen of lasofoxifene is different from the dosing regimen of the aromatase inhibitor. In some of these embodiments, the dosing quantity of lasofoxifene is different from the dosing quantity of the aromatase inhibitor. In some embodiments, the dosing schedule of lasofoxifene is different from the dosing schedule of the aromatase inhibitor. In some embodiments, the route of administration of lasofoxifene is different from the route of administration of the aromatase inhibitor.

In certain embodiments, the dosing regimen of lasofoxifene is the same as the dosing regimen of the aromatase inhibitor. In some embodiments, the dosing quantity of lasofoxifene is the same as the dosing quantity of the aromatase inhibitor. In some embodiments, the dosing schedule of lasofoxifene is the same as the dosing schedule of the aromatase inhibitor. In some embodiments, the route of administration of lasofoxifene is the same as the route of administration of the aromatase inhibitor.

In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for one year. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for two years. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for three years. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for four years. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for five years. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for six years. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for seven years. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for eight years. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for nine years. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for ten years. In some other embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to the patient for more than ten years. In certain embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor until the patient’s cancer progresses on therapy.

In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to increase the disease-free survival of the breast cancer patient. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to decrease the incidence of contralateral breast cancer. In some embodiments, lasofoxifene is administered as adjuvant therapy in combination with an aromatase inhibitor to prevent the recurrence or progression of the cancer.

6.2. Lasofoxifene

In various embodiments, the selected patient is treated with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. In some preferred embodiments, lasofoxifene is administered to the selected patient as lasofoxifene tartrate.

The term “pharmaceutically acceptable salt” refers to non-toxic pharmaceutically acceptable salts. See Gould, International Journal of Pharmaceutics 33: 201-217 (1986) and Berge et al., Journal of Pharmaceutical Sciences 66(1): 1-19 (1977). Other salts well known to those in the art may, however, be used. Representative organic or inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid. Representative organic or inorganic bases include, but are not limited to, basic or cationic salts such as benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium and zinc.

Embodiments also include prodrugs of the compounds disclosed herein. In general, such prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs ”, H. Bundgaard, Elsevier, 1985.

Some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are intended to be encompassed by some embodiments.

Where the processes for the preparation of the compounds as disclosed herein give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form or as individual enantiomers or diastereomers by either stereospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers or diastereomers by standard techniques, such as the formation of stereoisomeric pairs by salt formation with an optically active base, followed by fractional crystallization and regeneration of the free acid. The compounds may also be resolved by formation of stereoisomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column. It is to be understood that all stereoisomers, racemic mixtures, diastereomers, cis-trans isomers, and enantiomers thereof are encompassed by some embodiments.

6.3. Pharmaceutical Compositions

Methods for treatment of estrogen receptor positive (ER⁺) cancers include administering a therapeutically effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The lasofoxifene, the pharmaceutically acceptable salt, or the prodrug of the invention can be formulated in pharmaceutical compositions. In addition to lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof, the composition further comprises a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material can depend on the route of administration, e.g. oral, intravenous, transdermal, vaginal topical, or vaginal ring.

Pharmaceutical compositions for oral administration can be in tablet, capsule, powder or liquid form. A tablet can include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal oil, vegetable oil, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol can also be included.

For parenteral administration, the lasofoxifene will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer’s Injection, Lactated Ringer’s Injection. Preservatives, stabilizers, buffers, antioxidants and/or other additives can be included, as required.

Pharmaceutical compositions for vaginal topical administration can be in the form of ointment, cream, gel or lotion. The pharmaceutical compositions for vaginal topical administration often include water, alcohol, animal oil, vegetable oil, mineral oil or synthetic oil. Hydrocarbon (paraffin), wool fat, beeswax, macrogols, emulsifying wax or cetrimide can also be included.

A composition can be administered alone or in combination with other treatments, either simultaneously or sequentially, dependent upon the condition to be treated.

6.4. Treatment Regimens

In the methods of administering an effective amount of lasofoxifene in the form of a pharmaceutical composition as described above for treatment of ER⁺ cancer, the terms “treatment”, “treating”, and the like are used herein to generally mean obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic, in terms of completely or partially preventing a disease, condition, or symptoms thereof, and/or may be therapeutic in terms of a partial or complete cure for a disease or condition and/or adverse effect, such as a symptom, attributable to the disease or condition. “Treatment” as used herein covers any treatment of a disease or condition of a mammal, particularly a human, and includes: (a) preventing the disease or condition from occurring in a subject which may be predisposed to the disease or condition but has not yet been diagnosed as having it; (b) inhibiting the disease or condition (e.g., arresting its development); or (c) relieving the disease or condition (e.g., causing regression of the disease or condition, providing improvement in one or more symptoms). Improvements in any conditions can be readily assessed according to standard methods and techniques known in the art. The population of subjects treated by the method of the disease includes subjects suffering from the undesirable condition or disease, as well as subjects at risk for development of the condition or disease.

The term “effective amount” means a dose that produces the desired effect for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. See Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999).

6.4.1. Routes of Administration

In various embodiments, lasofoxifene is administered by oral, intravenous, transdermal, vaginal topical, or vaginal ring administration.

In some embodiments, lasofoxifene is administered to the patient by oral administration. In certain embodiments, lasofoxifene is administered at about 0.5 mg/day per os to about 10 mg/day per os, such as about 0.5 mg/day per os to about 5 mg/day per os, about 0.5 mg/day per os to about 5 mg/day per os, about 1 mg/day per os to about 5 mg/day per os, about 2 mg/day per os to about 5 mg/day per os, about 3 mg/day per os to about 5 mg/day per os, about 4 mg/day per os to about 5 mg/day per os, about 0.5 mg/day per os to about 4 mg/day per os, about 1 mg/day per os to about 4 mg/day per os, about 2 mg/day per os to about 4 mg/day per os, about 3 mg/day per os to about 4 mg/day per os, about 0.5 mg/day per os to about 3 mg/day per os, about 1 mg/day per os to about 3 mg/day per os, about 2 mg/day per os to about 3 mg/day per os, about 0.5 mg/day per os to about 2 mg/day per os, about 1 mg/day per os to about 2 mg/day per os, or about 0.5 mg/day per os to about 1 mg/day per os. In some embodiments, lasofoxifene is administered at about 0.5 mg/day per os. In some embodiments, lasofoxifene is administered at about 1 mg/day per os. In some embodiments, lasofoxifene is administered at about 1.5 mg/day per os. In some embodiments, lasofoxifene is administered at about 2 mg/day per os. In some embodiments, lasofoxifene is administered at about 2.5 mg/day per os. In some embodiments, lasofoxifene is administered at about 3 mg/day per os. In some embodiments, lasofoxifene is administered at about 3.5 mg/day per os. In some embodiments, lasofoxifene is administered at about 4 mg/day per os. In some embodiments, lasofoxifene is administered at about 4.5 mg/day per os. In some embodiments, lasofoxifene is administered at about 5 mg/day per os. In some embodiments, lasofoxifene is administered at about 6 mg/day per os. In some embodiments, lasofoxifene is administered at about 7 mg/day per os. In some embodiments, lasofoxifene is administered at about 8 mg/day per os. In some embodiments, lasofoxifene is administered at about 9 mg/day per os. In some embodiments, lasofoxifene is administered at about 10 mg/day per os. In some other embodiments, lasofoxifene is administered at more than 10 mg/day per os.

In certain embodiments, when lasofoxifene is administered to patient whose cancer has not acquired endocrine resistance, lasofoxifene can be administered at less than 0.5 mg/day per os for prevention of endocrine resistance. In certain embodiments, when lasofoxifene is administered to cancer patient as adjuvant treatment, lasofoxifene can be administered at less than 0.5 mg/day per os for prevention of endocrine resistance.

In certain embodiments, lasofoxifene is administered once every day. In certain embodiments, lasofoxifene is administered once every two days. In certain embodiments, lasofoxifene is administered once every three days. In certain embodiments, lasofoxifene is administered once every four days. In certain embodiments, lasofoxifene is administered once every five days. In certain embodiments, lasofoxifene is administered once every six days. In certain embodiments, lasofoxifene is administered once every week. In certain embodiments, lasofoxifene is administered once every two weeks. In certain embodiments, lasofoxifene is administered once every three weeks. In certain embodiments, lasofoxifene is administered once every month.

In some embodiments, lasofoxifene is administered to the patient by vaginal ring administration. In some of these embodiments, lasofoxifene is administered once every two weeks. In some of these embodiments, lasofoxifene is administered once every three weeks. In some of these embodiments, lasofoxifene is administered once every month. In some of these embodiments, lasofoxifene is administered once every two months. In some of these embodiments, lasofoxifene is administered once every three months. In some of these embodiments, lasofoxifene is administered once every four months.

In some embodiments, lasofoxifene is administered to ER⁺ cancer patient for one year. In some embodiments, lasofoxifene is administered to the patient for two years. In some embodiments, lasofoxifene is administered to the patient for three years. In some embodiments, lasofoxifene is administered to the patient for four years. In some embodiments, lasofoxifene is administered to the patient for five years. In some other embodiments, lasofoxifene is administered to the patient for more than five years. In certain embodiments, lasofoxifene is administered to the patient until the patient’s cancer progresses on therapy.

6.4.2. Combination Therapy

In various embodiments, lasofoxifene is administered either alone or in combination with other therapies. In certain embodiments, lasofoxifene is administered in combination with at least one other therapy. In some embodiments, lasofoxifene and other therapies are administered together (simultaneously). In some other embodiments, lasofoxifene and other therapies are administered at different times (sequentially).

In particular embodiments, the additional therapy that the patient is treated with is endocrine therapy. In various embodiments, the patient is treated with at least one line of additional endocrine therapy. In some embodiments, the patient is treated with one line of additional endocrine therapy. In some other embodiments, the patient is treated with multiple lines of additional endocrine therapy.

In some embodiments, the patient is treated with the additional endocrine therapy at the original doses. In some other embodiments, the patient is treated with the additional endocrine therapy at doses higher than original doses. In certain embodiments, the patient is treated with the additional endocrine therapy at doses lower than original doses.

In certain embodiments, the additional endocrine therapy is treatment with a selective ER modulator (SERM) other than lasofoxifene. In some of these embodiments, the selective ER modulator is selected from tamoxifen, raloxifene, bazedoxifene, toremifene, and ospermifene. In certain embodiments, the selective ER modulator is tamoxifen.

In certain embodiments, the additional endocrine therapy is treatment with a selective ER degrader (SERD). In some of these embodiments, the selective ER degrader is selected from fulvestrant, RAD1901, ARN-810 (GDC-0810), and AZD9496. In certain embodiments, the selective ER degrader is fulvestrant.

In certain embodiments, the additional endocrine therapy is treatment with an aromatase inhibitor. In some of these embodiments, the aromatase inhibitor is selected from exemestane (Aromasin^(®)), letrozole (Femara^(®)), and anastrozole (Arimidex^(®)).

In various embodiments, the additional therapy is administration to the patient of an effective amount of a cell cycle inhibitor. In certain embodiments, the additional therapy is administration of an effective amount of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. In some embodiments, the additional therapy is a CDK4/6 inhibitor selected from the group of palbociclib, abemaciclib, and ribociclib.

In some embodiments, the additional therapy is administration to the patient of an inhibitor of a pathway that cross-talks with and activates the ER transcriptional activity. In certain embodiments, the additional therapy is a mammalian target of rapamycin (mTOR) inhibitor. In specific embodiments, the mTOR inhibitor is Everolimus. In some of these embodiments, lasofoxifene in combination with Everolimus is administered to a postmenopausal woman with locally advanced or metastatic breast cancer who has progressed on a non-steroidal AI and/or fulvestrant either as monotherapy or in combination with a CDK4/6 inhibitor. In various embodiments, the additional therapy is a phosphoinositide 3-kinase (PI3K) inhibitor or a heat shock protein 90 (HSP90) inhibitor.

In various embodiments, the additional therapy is administration to the patient of an effective amount of a growth factor inhibitor. In certain embodiments, the additional therapy is a human epidermal growth factor receptor 2 (HER2) inhibitor. In some embodiments, the HER2 inhibitor is trastuzumab (Herceptin^(®)). In some other embodiments, the HER2 inhibitor is ado-trastuzumab emtansine (Kadcyla^(®)).

In some embodiments, the additional therapy is administering to the patient an effective amount of a histone deacetylase (HDAC) inhibitor. In various embodiments, the HDAC inhibitor is vorinostat (Zolinza^(®)), romidepsin (Istodax^(®)), chidamide (Epidaza^(®)), panobinostat (Farydak^(®)), belinostat (Beleodaq^(®), PXD101), valproic acid (Depakote^(®), Depakene^(®),Stavzor^(®)), mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat (ITF2357), quisinostat (JNJ-26481585), kevetrin, CUDC-101, AR-42, tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat (ACY-1215), or sulforaphane. In certain embodiments, the HDAC inhibitor is entinostat (MS-275) with the proviso that the patient is not treated with a HER2 inhibitor. In certain other embodiments, the HDAC inhibitor is vorinostat (Zolinza^(®)). In yet certain other embodiments, the HDAC inhibitor is romidepsin (Istodax^(®)R

In some embodiments, the additional therapy is administering to the patient an effective amount of a checkpoint inhibitor. In certain embodiments, the checkpoint inhibitor is an antibody. In some of these embodiments, the checkpoint inhibitor is an antibody specific for programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). In some embodiments, the PD-1 antibody is pembrolizumab (Keytruda^(®)) or nivolumab (Opdivo^(®)). In some embodiments, the CTLA-4 antibody is ipilimumab (Yervoy^(®)).

In certain embodiments, the additional therapy is administering to the patient an effective amount of cancer vaccine.

In some embodiments, the additional therapy is administering to the patient an effective amount of denosumab.

In some embodiments, the additional therapy is administering to the patient an effective amount of a serotonin-norepinephrine reuptake inhibitor (SNRI), a selective serotonin reuptake inhibitor (SSRI), or gabapentin. In certain embodiments, the SNRI is venlafaxine (Effexor^(®)).

6.4.3. Clinical Endpoints 6.4.3.1. Primary Clinical Endpoints

In various embodiments, the method comprises administering an amount of lasofoxifene effective to increase the disease-free survival of the ER⁺ cancer patient. In some embodiments, the method comprises administering lasofoxifene in an amount effective to reduce recurrence of ER⁺ cancer. In some embodiments, the method comprises administering lasofoxifene in an amount effective to increase time to recurrence of ER⁺ cancer. In some embodiments, the method comprises administering lasofoxifene in an amount effective to reduce metastasis of ER⁺ cancer. In some embodiments, the method comprises administering lasofoxifene in an amount effective to increase duration of progression-free survival of the ER⁺ cancer patient.

In various embodiments, the method increases the disease-free survival of the ER⁺ breast cancer patient. In certain embodiments, the method reduces recurrence of ER⁺ breast cancer. In certain embodiments, the method increases time to recurrence of ER⁺ breast cancer. In certain embodiments, the method reduces metastasis of ER⁺ breast cancer to bone. In certain embodiments, the method reduces metastasis of ER⁺ breast cancer to tissues other than bone. In certain embodiments, the method increases duration of progression-free survival of the ER⁺ breast cancer patient.

In various embodiments, the method increases the disease-free survival in ER⁺ cancer patient with endocrine resistance. In some embodiments, the method reduces recurrence of cancer in patient with endocrine resistance. In some embodiments, the method increases time to recurrence of cancer in patient with endocrine resistance. In some embodiments, the method reduces metastasis of cancer in patient with endocrine resistance. In some embodiments, the method increases duration of progression-free survival in ER⁺ cancer patient with endocrine resistance.

In some preferred embodiments, the method increases disease-free survival, reduces recurrence, increases time to recurrence, reduces metastasis, and/or increases duration of progression-free survival in patients with ER⁺ locally advanced or metastatic breast cancer that has developed endocrine resistance. In particular embodiments, the breast cancer has developed endocrine resistance by acquiring one or more of the ESR1 mutations discussed herein. In some embodiments, the method reduces the selective pressure and prevents the expansion of the endocrine resistant clones in ER⁺ locally advanced or metastatic breast cancer during treatment.

6.4.3.2. Secondary Clinical Endpoints

In some embodiments, the method is effective to prevent fracture and bone loss in women who are concurrently being treated with one or more drugs causing or predisposing to osteoporosis.

In some embodiments, the method is effective to decrease vaginal pH, increase vaginal lubrication, and/or improve vaginal cell maturation index in women who are concurrently being treated with one or more drugs causing or predisposing to vulvovaginal atrophy (VVA).

In some embodiments, the method reduces one or more symptoms of sexual dysfunction in women who are concurrently being treated with one or more drugs causing or predisposing to sexual dysfunction.

In some embodiments, the method treats hot flashes in women who are concurrently being treated with one or more drugs causing or predisposing to hot flashes.

In some embodiments, the method increases one or more quality of life measures selected from joint ache, urogenital symptoms, bone loss, and bone fractures.

6.5. Further Embodiments

Further embodiments are provided in the following numbered embodiments.

-   1. A method of treating locally advanced or metastatic breast cancer     in women, comprising:     -   a) selecting for treatment a patient who has been diagnosed with         estrogen receptor positive (ER⁺) locally advanced or metastatic         breast cancer; and     -   b) administering to the selected patient an effective amount of         lasofoxifene, a pharmaceutically acceptable salt thereof, or a         prodrug thereof. -   2. The method of embodiment 1, wherein the patient has previously     been treated with one or more lines of endocrine therapy. -   3. The method of embodiment 2, wherein the patient has previously     been treated with a plurality of lines of endocrine therapy. -   4. The method of embodiment 2 or embodiment 3, wherein the endocrine     therapy that the patient has previously been treated with is a     selective ER modulator (SERM). -   5. The method of embodiment 4, wherein the SERM is tamoxifen,     raloxifene, bazedoxifene, toremifene, or ospemifene. -   6. The method of embodiment 2 or embodiment 3, wherein the endocrine     therapy that the patient has previously been treated with is a     selective ER degrader (SERD). -   7. The method of embodiment 6, wherein the SERD is fulvestrant,     RAD1901, ARN-810 (GDC-0810), or AZD9496. -   8. The method of embodiment 2 or embodiment 3, wherein the endocrine     therapy that the patient has previously been treated with is an     aromatase inhibitor. -   9. The method of embodiment 8, wherein the aromatase inhibitor is     exemestane (Aromasin^(®)), letrozole (Femara^(®)), or anastrozole     (Arimidex^(®)). -   10. The method of any one of embodiments 2 to 9, wherein the patient     has disease progression after endocrine therapy. -   11. The method of any one of embodiments 1 to 10, wherein the     patient’s locally advanced or metastatic cancer is resistant to     endocrine therapy other than lasofoxifene. -   12. The method of any one of embodiments 1 to 11, wherein the     patient’s locally advanced or metastatic cancer has at least one     gain of function missense mutation within the ligand binding domain     (LBD) of the Estrogen Receptor 1 (ESR1) gene. -   13. The method of embodiment 12, wherein the patient has previously     been determined to have at least one gain of function missense     mutation within the ligand binding domain (LBD) of the Estrogen     Receptor 1 (ESR1) gene. -   14. The method of embodiment 13, further comprising the earlier step     of:     -   determining that the patient has at least one gain of function         missense mutation within the ligand binding domain (LBD) of the         Estrogen Receptor 1 (ESR1) gene. -   15. The method of any one of embodiments 12 to 14, wherein the at     least one of gain of function missense mutation is in any one of     amino acids D538, Y537, L536, P535, V534, S463, V392, and E380. -   16. The method of embodiment 15, wherein the at least one gain of     function missense mutation is in the amino acid D538. -   17. The method of embodiment 16, wherein the mutation is D538G. -   18. The method of embodiment 15, wherein the at least one gain of     function missense mutation is in the amino acid Y537. -   19. The method of embodiment 18, wherein the mutation is Y537S,     Y537N, Y537C, or Y537Q. -   20. The method of embodiment 19, wherein the mutation is Y537C. -   21. The method of embodiment 15, wherein the at least one gain of     function missense mutation is in the amino acid L536. -   22. The method of embodiment 21, wherein the mutation is L536R or     L536Q. -   23. The method of embodiment 15, wherein the at least one gain of     function missense mutation is in the amino acid P535. -   24. The method of embodiment 23, wherein the mutation is P535H. -   25. The method of embodiment 15, wherein the at least one gain of     function missense mutation is in the amino acid V534. -   26. The method of embodiment 25, wherein the mutation is V534E. -   27. The method of embodiment 15, wherein the at least one gain of     function missense mutation is in the amino acid S463. -   28. The method of embodiment 27, wherein the mutation is S463P. -   29. The method of embodiment 15, wherein the at least one gain of     function missense mutation is in the amino acid V392. -   30. The method of embodiment 29, wherein the mutation is V392I. -   31. The method of embodiment 15, wherein the at least one gain of     function missense mutation is in the amino acid E380. -   32. The method of embodiment 31, wherein the mutation is E380Q. -   33. The method of any one of embodiments 12 to 32, wherein the serum     estradiol level of the patient is at least 0.35 ng/dL. -   34. The method of any one of embodiments 12 to 32, wherein the serum     estradiol level of the patient is about 0.30 ng/dL to about 0.35     ng/dL. -   35. The method of any one of embodiments 12 to 32, wherein the serum     estradiol level of the patient is about 0.25 ng/dL to about 0.30     ng/dL. -   36. The method of any one of embodiments 1 to 35, wherein     lasofoxifene is administered as lasofoxifene tartrate. -   37. The method of any one of embodiments 1 to 36, wherein     lasofoxifene is administered by oral, intravenous, transdermal,     vaginal topical, or vaginal ring administration. -   38. The method of embodiment 37, wherein lasofoxifene is     administered by oral administration. -   39. The method of embodiment 38, wherein lasofoxifene is     administered at about 0.5 mg/day per os to about 10 mg/day per os. -   40. The method of embodiment 39, wherein lasofoxifene is     administered at about 0.5 mg/day per os to about 5 mg/day per os. -   41. The method of embodiment 40, wherein lasofoxifene is     administered at about 1 mg/day per os to about 5 mg/day per os. -   42. The method of embodiment 40, wherein lasofoxifene is     administered at 1 mg/day per os. -   43. The method of embodiment 40, wherein lasofoxifene is     administered at 5 mg/day per os. -   44. The method of any one of embodiments 1 to 43, wherein     lasofoxifene is administered once every day, once every two days,     once every three days, once every four days, once every five days,     once every six days, once every week, once every two weeks, once     every three weeks, or once every month. -   45. The method of any one of embodiments 1 to 44, further comprising     treating said patient with at least one additional endocrine     therapy. -   46. The method of embodiment 45, wherein said patient is treated     with the additional endocrine therapy at original doses. -   47. The method of embodiment 45, wherein said patient is treated     with the additional endocrine therapy at doses higher than original     doses. -   48. The method of any one of embodiments 45 to 47, wherein the     additional endocrine therapy is treatment with a selective ER     modulator (SERM) other than lasofoxifene. -   49. The method of any one of embodiments 45 to 47, wherein the     additional endocrine therapy is treatment with a selective ER     degrader (SERD). -   50. The method of any one of embodiments 45 to 47, wherein the     additional endocrine therapy is treatment with an aromatase     inhibitor. -   51. The method of any one of embodiments 1 to 44, further comprising     administering to said patient an effective amount of     cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. -   52. The method of embodiment 51, wherein said CDK4/6 inhibitor is     palbociclib, abemaciclib, or ribociclib. -   53. The method of any one of embodiments 1 to 44, further comprising     administering to said patient an effective amount of mammalian     target of rapamycin (mTOR) inhibitor. -   54. The method of embodiment 53, wherein said mTOR inhibitor is     Everolimus. -   55. The method of any one of embodiments 1 to 44, further comprising     administering to said patient an effective amount of     phosphoinositide 3-kinase (PI3K) inhibitor or heat shock protein 90     (HSP90) inhibitor. -   56. The method of any one of embodiments 1 to 44, further comprising     administering to said patient an effective amount of human epidermal     growth factor receptor 2 (HER2) inhibitor. -   57. The method of embodiment 56, wherein said HER2 inhibitor is     trastuzumab (Herceptin^(®)) or ado-trastuzumab emtansine     (Kadcyla^(®)). -   58. The method of any one of embodiments 1 to 44, further comprising     administering to said patient an effective amount of a histone     deacetylase (HDAC) inhibitor. -   59. The method of embodiment 58, wherein said HDAC inhibitor is     vorinostat (Zolinza^(®)), romidepsin (Istodax^(®)), chidamide     (Epidaza^(®)), panobinostat (Farydak^(®)), belinostat (Beleodaq^(®),     PXD101), valproic acid (Depakote^(®), Depakene^(®),Stavzor^(®)),     mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat     (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat     (ITF2357), quisinostat (JNJ-26481585), kevetrin, CUDC-101, AR-42,     tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat     (ACY-1215), or sulforaphane. -   60. The method of any one of embodiments 1 to 44, further comprising     administering to said patient an effective amount of a checkpoint     inhibitor. -   61. The method of embodiment 60, wherein said checkpoint inhibitor     is an antibody specific for programmed cell death protein 1 (PD-1),     programmed death-ligand 1 (PD-L1), or cytotoxic     T-lymphocyte-associated protein 4 (CTLA-4). -   62. The method of embodiment 61, wherein said PD-1 antibody is     pembrolizumab (Keytruda^(®)) or nivolumab (Opdivo^(®)). -   63. The method of embodiment 61, wherein said CTLA-4 antibody is     ipilimumab (Yervoy^(®)). -   64. The method of any one of embodiments 1 to 44, further comprising     administering to said patient an effective amount of cancer vaccine. -   65. The method of any one of embodiments 1 to 64, wherein the     patient is premenopausal. -   66. The method of embodiment 65, wherein the patient has locally     advanced or metastatic ER+/HER2- breast cancer. -   67. The method of embodiment 65, wherein the patient has progressed     on her first hormonal treatment while on a non-steroid aromatase     inhibitor (AI), fulvestrant, AI in combination with a CDK4/6     inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor. -   68. The method of any one of embodiments 1 to 64, wherein the     patient is perimenopausal. -   69. The method of embodiment 68, wherein the patient has locally     advanced or metastatic ER+/HER2- breast cancer. -   70. The method of embodiment 69, wherein the patient has progressed     on her first hormonal treatment while on a non-steroid aromatase     inhibitor (AI), fulvestrant, AI in combination with a CDK4/6     inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor. -   71. The method of any one of embodiments 1 to 64, wherein the     patient is postmenopausal. -   72. The method of embodiment 71, wherein the patient has locally     advanced or metastatic ER+/HER2- breast cancer. -   73. The method of embodiment 72, wherein the patient has progressed     on her first hormonal treatment while on a non-steroid aromatase     inhibitor (AI), fulvestrant, AI in combination with a CDK4/6     inhibitor, or fulvestrant in combination with a CDK4/6 inhibitor. -   74. A method of treating primary breast cancer in women, comprising:     -   a) selecting for treatment a patient who has been diagnosed with         estrogen receptor positive (ER⁺) primary breast cancer; and     -   b) administering to the selected patient an effective amount of         lasofoxifene, a pharmaceutically acceptable salt thereof, or a         prodrug thereof. -   75. The method of embodiment 74, wherein lasofoxifene is     administered as lasofoxifene tartrate. -   76. The method of embodiment 74 or embodiment 75, wherein     lasofoxifene is administered by oral, intravenous, transdermal,     vaginal topical, or vaginal ring administration. -   77. The method of embodiment 76, wherein lasofoxifene is     administered by oral administration. -   78. The method of embodiment 77, wherein lasofoxifene is     administered at about 0.5 mg/day per os to about 10 mg/day per os. -   79. The method of embodiment 78, wherein lasofoxifene is     administered at about 0.5 mg/day per os to about 5 mg/day per os. -   80. The method of embodiment 79, wherein lasofoxifene is     administered at about 1 mg/day per os to about 5 mg/day per os. -   81. The method of embodiment 79, wherein lasofoxifene is     administered at 1 mg/day per os. -   82. The method of embodiment 79, wherein lasofoxifene is     administered at 5 mg/day per os. -   83. The method of any one of embodiments 74 to 82, wherein     lasofoxifene is administered once every day, once every two days,     once every three days, once every four days, once every five days,     once every six days, once every week, once every two weeks, once     every three weeks, or once every month. -   84. The method of any one of embodiments 74 to 83, further     comprising treating said patient with at least one additional     endocrine therapy. -   85. The method of embodiment 84, wherein said patient is treated     with the additional endocrine therapy at original doses. -   86. The method of embodiment 84, wherein said patient is treated     with the additional endocrine therapy at doses higher than original     doses. -   87. The method of any one of embodiments 84 to 86, wherein the     additional endocrine therapy is treatment with a selective ER     modulator (SERM) other than lasofoxifene. -   88. The method of any one of embodiments 84 to 86, wherein the     additional endocrine therapy is treatment with a selective ER     degrader (SERD). -   89. The method of any one of embodiments 84 to 86, wherein the     additional endocrine therapy is treatment with an aromatase     inhibitor. -   90. The method of any one of embodiments 74 to 83, further     comprising administering to said patient an effective amount of     cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. -   91. The method of embodiment 90, wherein said CDK4/6 inhibitor is     palbociclib, abemaciclib, or ribociclib. -   92. The method of any one of embodiments 74 to 83, further     comprising administering to said patient an effective amount of     mammalian target of rapamycin (mTOR) inhibitor. -   93. The method of embodiment 92, wherein said mTOR inhibitor is     Everolimus. -   94. The method of any one of embodiments 74 to 83, further     comprising administering to said patient an effective amount of     phosphoinositide 3-kinase (PI3K) inhibitor or heat shock protein 90     (HSP90) inhibitor. -   95. The method of any one of embodiments 74 to 83, further     comprising administering to said patient an effective amount of     human epidermal growth factor receptor 2 (HER2) inhibitor. -   96. The method of embodiment 95, wherein said HER2 inhibitor is     trastuzumab (Herceptin^(®)) or ado-trastuzumab emtansine     (Kadcyla^(®)). -   97. The method of any one of embodiments 74 to 83, further     comprising administering to said patient an effective amount of a     histone deacetylase (HDAC) inhibitor. -   98. The method of embodiment 97, wherein said HDAC inhibitor is     vorinostat (Zolinza^(®)), romidepsin (Istodax^(®)), chidamide     (Epidaza^(®)), panobinostat (Farydak^(®)), belinostat (Beleodaq^(®),     PXD101), valproic acid (Depakote^(®), Depakene^(®),Stavzor^(®)),     mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat     (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat     (ITF2357), quisinostat (JNJ-26481585), kevetrin, CUDC-101, AR-42,     tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat     (ACY-1215), or sulforaphane. -   99. The method of any one of embodiments 74 to 83, further     comprising administering to said patient an effective amount of     checkpoint inhibitor. -   100. The method of embodiment 99, wherein said checkpoint inhibitor     is an antibody specific for programmed cell death protein 1 (PD-1),     programmed death-ligand 1 (PD-L1), or cytotoxic     T-lymphocyte-associated protein 4 (CTLA-4). -   101. The method of embodiment 100, wherein said PD-1 antibody is     pembrolizumab (Keytruda^(®)) or nivolumab (Opdivo^(®)). -   102. The method of embodiment 100, wherein said CTLA-4 antibody is     ipilimumab (Yervoy^(®)). -   103. The method of any one of embodiments 74 to 83, further     comprising administering to said patient an effective amount of     cancer vaccine. -   104. The method of any one of embodiments 74 to 103, wherein the     patient is premenopausal. -   105. The method of any one of embodiments 74 to 103, wherein the     patient is perimenopausal. -   106. The method of any one of embodiments 74 to 103, wherein the     patient is postmenopausal. -   107. A method of adjuvant therapy of estrogen receptor positive     (ER⁺) breast cancer, comprising:     -   administering to a patient who has received primary treatment         for ER⁺ breast cancer an effective amount of lasofoxifene, a         pharmaceutically acceptable salt thereof, or a prodrug thereof,         in combination with an aromatase inhibitor. -   108. The method of embodiment 107, wherein lasofoxifene is     administered continuously during the administration of the aromatase     inhibitor. -   109. The method of embodiment 107, wherein lasofoxifene is     administered cyclically during the administration of the aromatase     inhibitor. -   110. The method of any one of embodiments 107 to 109, wherein the     dosing regimen of lasofoxifene is different from the dosing regimen     of the aromatase inhibitor. -   111. The method of any one of embodiments 107 to 110, wherein     lasofoxifene is administered as lasofoxifene tartrate. -   112. The method of any one of embodiments 107 to 111, wherein the     aromatase inhibitor is exemestane (Aromasin^(®)), letrozole     (Femara^(®)), or anastrozole (Arimidex^(®)). -   113. The method of any one of embodiments 107 to 112, wherein     lasofoxifene is administered by oral, intravenous, transdermal,     vaginal topical, or vaginal ring administration. -   114. The method of embodiment 113, wherein lasofoxifene is     administered by oral administration. -   115. The method of embodiment 114, wherein lasofoxifene is     administered at about 0.5 mg/day per os to about 10 mg/day per os. -   116. The method of embodiment 115, wherein lasofoxifene is     administered at about 0.5 mg/day per os to about 5 mg/day per os. -   117. The method of embodiment 116, wherein lasofoxifene is     administered at about 1 mg/day per os to about 5 mg/day per os. -   118. The method of embodiment 116, wherein lasofoxifene is     administered at 1 mg/day per os. -   119. The method of embodiment 116, wherein lasofoxifene is     administered at 5 mg/day per os. -   120. The method of any one of embodiments 107 to 119, wherein     lasofoxifene is administered once every day, once every two days,     once every three days, once every four days, once every five days,     once every six days, once every week, once every two weeks, once     every three weeks, or once every month. -   121. The method of any one of embodiments 107 to 120, further     comprising treating said patient with an additional endocrine     therapy. -   122. The method of embodiment 121, wherein the additional endocrine     therapy is treatment with a selective ER degrader (SERD). -   123. The method of any one of embodiments 107 to 120, further     comprising administering to said patient an effective amount of     cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. -   124. The method of embodiment 123, wherein said CDK4/6 inhibitor is     palbociclib, abemaciclib, or ribociclib. -   125. The method of any one of embodiments 107 to 120, further     comprising administering to said patient an effective amount of     mammalian target of rapamycin (mTOR) inhibitor. -   126. The method of embodiment 125, wherein said mTOR inhibitor is     Everolimus. -   127. The method of any one of embodiments 107 to 120, further     comprising administering to said patient an effective amount of     phosphoinositide 3-kinase (PI3K) inhibitor or heat shock protein 90     (HSP90) inhibitor. -   128. The method of any one of embodiments 107 to 120, further     comprising administering to said patient an effective amount of     human epidermal growth factor receptor 2 (HER2) inhibitor. -   129. The method of embodiment 128, wherein said HER2 inhibitor is     trastuzumab (Herceptin^(®)) or ado-trastuzumab emtansine     (Kadcyla^(®)). -   130. The method of any one of embodiments 107 to 120, further     comprising administering to said patient an effective amount of a     histone deacetylase (HDAC) inhibitor. -   131. The method of embodiment 130, wherein said HDAC inhibitor is     vorinostat (Zolinza^(®)), romidepsin (Istodax^(®)), chidamide     (Epidaza^(®)), panobinostat (Farydak^(®)), belinostat (Beleodaq^(®),     PXD101), valproic acid (Depakote^(®), Depakene^(®),Stavzor®),     mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat     (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat     (ITF2357), quisinostat (JNJ-26481585), kevetrin, CUDC-101, AR-42,     tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat     (ACY-1215), or sulforaphane. -   132. The method of any one of embodiments 107 to 120, further     comprising administering to said patient an effective amount of     checkpoint inhibitor. -   133. The method of embodiment 132, wherein said checkpoint inhibitor     is an antibody specific for programmed cell death protein 1 (PD-1),     programmed death-ligand 1 (PD-L1), or cytotoxic     T-lymphocyte-associated protein 4 (CTLA-4). -   134. The method of embodiment 133, wherein said PD-1 antibody is     pembrolizumab (Keytruda^(®)) or nivolumab (Opdivo^(®)). -   135. The method of embodiment 133, wherein said CTLA-4 antibody is     ipilimumab (Yervoy®). -   136. The method of any one of embodiments 107 to 120, further     comprising administering to said patient an effective amount of     cancer vaccine. -   137. The method of any one of embodiments 107 to 136, wherein     lasofoxifene is administered in an amount and on a schedule     sufficient to improve bone mass. -   138. The method of any one of embodiments 107 to 136, wherein     lasofoxifene is administered in an amount and on a schedule     sufficient to improve symptoms of VVA. -   139. The method of any one of embodiments 107 to 138, wherein the     patient is premenopausal. -   140. The method of any one of embodiments 107 to 138, wherein the     patient is perimenopausal. -   141. The method of any one of embodiments 107 to 138, wherein the     patient is postmenopausal. -   142. A method of treating cancers other than breast cancer in women,     comprising:     -   a) selecting for treatment a patient who has been diagnosed with         estrogen receptor positive (ER⁺) cancer, other than breast         cancer, and has at least one gain of function mutations in the         Estrogen Receptor 1 (ESR1) gene; and     -   b) administering to the selected patient an effective amount of         lasofoxifene, a pharmaceutically acceptable salt thereof, or a         prodrug thereof. -   143. The method of embodiment 142, wherein the patient has been     diagnosed with ER⁺ ovarian cancer. -   144. The method of embodiment 142, wherein the patient has been     diagnosed with ER⁺ lung cancer. -   145. The method of any one of embodiments 142 to 144, wherein     lasofoxifene is administered as lasofoxifene tartrate. -   146. The method of any one of embodiments 142 to 145, wherein     lasofoxifene is administered by oral, intravenous, transdermal,     vaginal topical, or vaginal ring administration. -   147. The method of embodiment 146, wherein lasofoxifene is     administered by oral administration. -   148. The method of embodiment 147, wherein lasofoxifene is     administered at about 0.5 mg/day per os to about 10 mg/day per os. -   149. The method of embodiment 148, wherein lasofoxifene is     administered at about 0.5 mg/day per os to about 5 mg/day per os. -   150. The method of embodiment 149, wherein lasofoxifene is     administered at about 1 mg/day per os to about 5 mg/day per os. -   151. The method of embodiment 149, wherein lasofoxifene is     administered at 1 mg/day per os. -   152. The method of embodiment 149, wherein lasofoxifene is     administered at 5 mg/day per os. -   153. The method of any one of embodiments 142 to 152, wherein     lasofoxifene is administered once every day, once every two days,     once every three days, once every four days, once every five days,     once every six days, once every week, once every two weeks, once     every three weeks, or once every month. -   154. The method of any one of embodiments 142 to 153, further     comprising treating said patient with at least one additional     endocrine therapy. -   155. The method of embodiment 154, wherein said patient is treated     with the additional endocrine therapy at original doses. -   156. The method of embodiment 154, wherein said patient is treated     with the additional endocrine therapy at doses higher than original     doses. -   157. The method of any one of embodiments 154 to 156, wherein the     additional endocrine therapy is treatment with a selective ER     modulator (SERM) other than lasofoxifene. -   158. The method of any one of embodiments 154 to 156, wherein the     additional endocrine therapy is treatment with a selective ER     degrader (SERD). -   159. The method of any one of embodiments 154 to 156, wherein the     additional endocrine therapy is treatment with an aromatase     inhibitor. -   160. The method of any one of embodiments 142 to 153, further     comprising administering to said patient an effective amount of     cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. -   161. The method of embodiment 160, wherein said CDK4/6 inhibitor is     palbociclib, abemaciclib, or ribociclib. -   162. The method of any one of embodiments 142 to 153, further     comprising administering to said patient an effective amount of     mammalian target of rapamycin (mTOR) inhibitor. -   163. The method of embodiment 162, wherein said mTOR inhibitor is     Everolimus. -   164. The method of any one of embodiments 142 to 153, further     comprising administering to said patient an effective amount of     phosphoinositide 3-kinase (PI3K) inhibitor or heat shock protein 90     (HSP90) inhibitor. -   165. The method of any one of embodiments 142 to 153, further     comprising administering to said patient an effective amount of     human epidermal growth factor receptor 2 (HER2) inhibitor. -   166. The method of embodiment 165, wherein said HER2 inhibitor is     trastuzumab (Herceptin^(®)) or ado-trastuzumab emtansine     (Kadcyla^(®)). -   167. The method of any one of embodiments 142 to 153, further     comprising administering to said patient an effective amount of a     histone deacetylase (HDAC) inhibitor. -   168. The method of embodiment 167, wherein said HDAC inhibitor is     vorinostat (Zolinza^(®)), romidepsin (Istodax^(®)), chidamide     (Epidaza^(®)), panobinostat (Farydak^(®)), belinostat (Beleodaq^(®),     PXD101), valproic acid (Depakote^(®), Depakene^(®), Stavzor^(®)),     mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat     (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat     (ITF2357), quisinostat (JNJ-26481585), kevetrin, CUDC-101, AR-42,     tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat     (ACY-1215), or sulforaphane. -   169. The method of any one of embodiments 142 to 153, further     comprising administering to said patient an effective amount of     checkpoint inhibitor. -   170. The method of embodiment 169, wherein said checkpoint inhibitor     is an antibody specific for programmed cell death protein 1 (PD-1),     programmed death-ligand 1 (PD-L1), or cytotoxic     T-lymphocyte-associated protein 4 (CTLA-4). -   171. The method of embodiment 170, wherein said PD-1 antibody is     pembrolizumab (Keytruda^(®)) or nivolumab (Opdivo^(®)). -   172. The method of embodiment 170, wherein said CTLA-4 antibody is     ipilimumab (Yervoy^(®)). -   173. The method of any one of embodiments 142 to 153, further     comprising administering to said patient an effective amount of     cancer vaccine. -   174. The method of any one of embodiments 142 to 173, wherein the     patient is premenopausal. -   175. The method of any one of embodiments 142 to 173, wherein the     patient is perimenopausal. -   176. The method of any one of embodiments 142 to 173, wherein the     patient is postmenopausal. -   177. A method of treating a female patient suffering from breast     cancer who is at risk of acquiring a gain of function missense     mutation within the ligand binding domain (LBD) of the Estrogen     Receptor 1 (ESR1) gene, comprising administering to the female     patient an effective amount of lasofoxifene, a pharmaceutically     acceptable salt thereof, or a prodrug thereof. -   178. A method of treating a female patient suffering from breast     cancer who is at risk of acquiring resistance to endocrine therapy,     optionally wherein the endocrine therapy is (i) selective ER     modulator (SERM) therapy, (ii) selective ER degrader (SERD)     therapy, (iii) aromatase inhibitor (AI) therapy, or (iv) any     combination of (i), (ii) and/or (iii), comprising administering to     the female patient an effective amount of lasofoxifene, a     pharmaceutically acceptable salt thereof, or a prodrug thereof. -   179. The method of embodiment 177 or embodiment 178, wherein the     patient has primary breast cancer. -   180. The method of embodiment 179, wherein the primary breast cancer     is locally advanced. -   181. The method of any one of embodiments 177 to 180, wherein the     patient has been treated with endocrine therapy, optionally wherein     the endocrine therapy is (i) selective ER modulator (SERM)     therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase     inhibitor (AI) therapy, or (iv) any combination of (i), (ii) and/or     (iii). -   182. A method of treating a female patient suffering from estrogen     receptor positive (ER⁺) primary breast cancer, comprising     administering to a female patient an effective amount of     lasofoxifene, a pharmaceutically acceptable salt thereof, or a     prodrug thereof. -   183. The method of embodiment 182, wherein the patient is at risk of     acquiring resistance to endocrine therapy, optionally wherein the     endocrine therapy is (i) selective ER modulator (SERM) therapy, (ii)     selective ER degrader (SERD) therapy, (iii) aromatase inhibitor (AI)     therapy, or (iv) any combination of (i), (ii) and/or (iii). -   184. The method of embodiment 182 or embodiment 183, wherein the     primary breast cancer is locally advanced. -   185. The method of any one of embodiments 182 to 184, wherein the     patient has been treated with endocrine therapy, optionally wherein     the endocrine therapy is (i) selective ER modulator (SERM)     therapy, (ii) selective ER degrader (SERD) therapy, (iii) aromatase     inhibitor (AI) therapy, or (iv) any combination of (i), (ii) and/or     (iii). -   186. A method of treating a female patient suffering from estrogen     receptor positive (ER⁺) locally advanced or metastatic breast     cancer, comprising administering to a female patient an effective     amount of lasofoxifene, a pharmaceutically acceptable salt thereof,     or a prodrug thereof. -   187. The method of embodiment 186, wherein the patient has     previously been treated with one or more lines of endocrine therapy. -   188. The method of embodiment 186, wherein the patient has     previously been treated with a plurality of lines of endocrine     therapy. -   189. The method of any one of embodiments 186 to 188, wherein the     patient has disease progression after endocrine therapy. -   190. The method of any one of embodiments 186 to 188, wherein the     endocrine therapy that the patient has previously been treated with     is a selective ER modulator (SERM). -   191. The method of embodiment 190, wherein the SERM is tamoxifen,     raloxifene, bazedoxifene, toremifene, or ospemifene. -   192. The method any one of embodiments 186 to 188, wherein the     endocrine therapy that the patient has previously been treated with     is a selective ER degrader (SERD). -   193. The method of embodiment 192, wherein the SERD is fulvestrant,     RAD1901, ARN-810 (GDC-0810), or AZD9496. -   194. The method of any one of embodiments 186 to 188, wherein the     endocrine therapy that the patient has previously been treated with     is an aromatase inhibitor. -   195. The method of embodiment 194, wherein the aromatase inhibitor     is exemestane (Aromasin^(®)), letrozole (Femara^(®)), or anastrozole     (Arimidex^(®)). -   196. The method of any one of embodiments 187 to 195, wherein the     patient has disease progression after endocrine therapy. -   197. The method of any one of embodiments 186 to 196, wherein the     patient’s locally advanced or metastatic cancer is resistant to     endocrine therapy other than lasofoxifene. -   198. The method of any one of embodiments 186 to 197, wherein the     patient has cancer cells with at least one gain of function missense     mutation within the ligand binding domain (LBD) of the Estrogen     Receptor 1 (ESR1) gene. -   199. The method of embodiment 198, wherein the patient has     previously been determined to have at least one gain of function     missense mutation within the ligand binding domain (LBD) of the     Estrogen Receptor 1 (ESR1) gene. -   200. The method of embodiment 197, further comprising the earlier     step of:     -   determining that the patient has at least one gain of function         missense mutation within the ligand binding domain (LBD) of the         Estrogen Receptor 1 (ESR1) gene. -   201. The method of any one of embodiments 198 to 198, wherein the at     least one of gain of function missense mutation is in any one of     amino acids D538, Y537, L536, P535, V534, S463, V392, and E380.. -   202. The method of embodiment 201, wherein the at least one gain of     function missense mutation is in the amino acid D538. -   203. The method of embodiment 202, wherein the mutation is D538G. -   204. The method of embodiment 201, wherein the at least one gain of     function missense mutation is in the amino acid Y537. -   205. The method of embodiment 204, wherein the mutation is Y537S,     Y537N, Y537C, or Y537Q. -   206. The method of embodiment 205, wherein the mutation is Y537C. -   207. The method of embodiment 201, wherein the at least one gain of     function missense mutation is in the amino acid L536. -   208. The method of embodiment 207, wherein the mutation is L536R or     L536Q. -   209. The method of embodiment 201, wherein the at least one gain of     function missense mutation is in the amino acid P535. -   210. The method of embodiment 209, wherein the mutation is P535H. -   211. The method of embodiment 201, wherein the at least one gain of     function missense mutation is in the amino acid V534. -   212. The method of embodiment 211, wherein the mutation is V534E. -   213. The method of embodiment 201, wherein the at least one gain of     function missense mutation is in the amino acid S463. -   214. The method of embodiment 213, wherein the mutation is S463P. -   215. The method of embodiment 201, wherein the at least one gain of     function missense mutation is in the amino acid V392. -   216. The method of embodiment 215, wherein the mutation is V392I. -   217. The method of embodiment 201, wherein the at least one gain of     function missense mutation is in the amino acid E380. -   218. The method of embodiment 217, wherein the mutation is E380Q. -   219. The method of any one of embodiments 177 to 218, wherein     lasofoxifene is administered as lasofoxifene tartrate. -   220. The method of any one of embodiments 177 to 219, wherein     lasofoxifene is administered by oral, intravenous, transdermal,     vaginal topical, or vaginal ring administration. -   221. The method of embodiment 220, wherein lasofoxifene is     administered by oral administration. -   222. The method of embodiment 221, wherein lasofoxifene is     administered at about 0.5 mg/day per os to about 10 mg/day per os. -   223. The method of embodiment 222, wherein lasofoxifene is     administered at about 0.5 mg/day per os to about 5 mg/day per os. -   224. The method of embodiment 223, wherein lasofoxifene is     administered at about 1 mg/day per os to about 5 mg/day per os. -   225. The method of embodiment 223, wherein lasofoxifene is     administered at 1 mg/day per os. -   226. The method of embodiment 223, wherein lasofoxifene is     administered at 5 mg/day per os. -   227. The method of any one of embodiments 177 to 226, wherein     lasofoxifene is administered once every day, once every two days,     once every three days, once every four days, once every five days,     once every six days, once every week, once every two weeks, once     every three weeks, or once every month. -   228. The method of any one of embodiments 177 to 227, further     comprising treating said patient with at least one additional     endocrine therapy. -   229. The method of embodiment 228, wherein said patient is treated     with the additional endocrine therapy at original doses. -   230. The method of embodiment 228, wherein said patient is treated     with the additional endocrine therapy at doses higher than original     doses. -   231. The method of any one of embodiments 228 to 230, wherein the     additional endocrine therapy is treatment with a selective ER     modulator (SERM) other than lasofoxifene. -   232. The method of any one of embodiments 228 to 230, wherein the     additional endocrine therapy is treatment with a selective ER     degrader (SERD). -   233. The method of any one of embodiments 228 to 230, wherein the     additional endocrine therapy is treatment with an aromatase     inhibitor. -   234. The method of any one of embodiments 177 to 227, further     comprising administering to said patient an effective amount of     cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. -   235. The method of embodiment 234, wherein said CDK4/6 inhibitor is     palbociclib, abemaciclib, or ribociclib. -   236. The method of any one of embodiments 177 to 227, further     comprising administering to said patient an effective amount of     mammalian target of rapamycin (mTOR) inhibitor. -   237. The method of embodiment 236, wherein said mTOR inhibitor is     Everolimus. -   238. The method of any one of embodiments 177 to 227, further     comprising administering to said patient an effective amount of     phosphoinositide 3-kinase (PI3K) inhibitor or heat shock protein 90     (HSP90) inhibitor. -   239. The method of any one of embodiments 177 to 227, further     comprising administering to said patient an effective amount of     human epidermal growth factor receptor 2 (HER2) inhibitor. -   240. The method of embodiment 239, wherein said HER2 inhibitor is     trastuzumab (Herceptin^(®)) or ado-trastuzumab emtansine     (Kadcyla^(®)). -   241. The method of any one of embodiments 177 to 227, further     comprising administering to said patient an effective amount of a     histone deacetylase (HDAC) inhibitor. -   242. The method of embodiment 241, wherein said HDAC inhibitor is     vorinostat (Zolinza^(®)), romidepsin (Istodax®), chidamide     (Epidaza^(®)), panobinostat (Farydak^(®)), belinostat (Beleodaq^(®),     PXD101), valproic acid (Depakote^(®), Depakene^(®), Stavzor^(®)),     mocetinostat (MGCD0103), abexinostat (PCI-24781), entinostat     (MS-275), pracinostat (SB939), resminostat (4SC-201), givinostat     (ITF2357), quisinostat (JNJ-26481585), kevetrin, CUDC-101, AR-42,     tefinostat (CHR-2835), CHR-3996, 4SC202, CG200745, rocilinostat     (ACY-1215), or sulforaphane. -   243. The method of any one of embodiments 177 to 227, further     comprising administering to said patient an effective amount of a     checkpoint inhibitor. -   244. The method of embodiment 243, wherein said checkpoint inhibitor     is an antibody specific for programmed cell death protein 1 (PD-1),     programmed death-ligand 1 (PD-L1), or cytotoxic     T-lymphocyte-associated protein 4 (CTLA-4). -   245. The method of embodiment 244, wherein said PD-1 antibody is     pembrolizumab (Keytruda^(®)) or nivolumab (Opdivo^(®)). -   246. The method of embodiment 244, wherein said CTLA-4 antibody is     ipilimumab (Yervoy^(®)). -   247. The method of any one of embodiments 177 to 227, further     comprising administering to said patient an effective amount of     cancer vaccine. -   248. The method of any one of embodiments 177 to 247, wherein the     patient is premenopausal. -   249. The method of embodiment 248, wherein the patient has locally     advanced or metastatic ER+/HER2- breast cancer. -   250. The method of embodiment 249, wherein the patient has     progressed on her first hormonal treatment while on a non-steroid     aromatase inhibitor (AI), fulvestrant, AI in combination with a     CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6     inhibitor. -   251. The method of any one of embodiments 177 to 247, wherein the     patient is perimenopausal. -   252. The method of embodiment 251, wherein the patient has locally     advanced or metastatic ER+/HER2- breast cancer. -   253. The method of embodiment 252, wherein the patient has     progressed on her first hormonal treatment while on a non-steroid     aromatase inhibitor (AI), fulvestrant, AI in combination with a     CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6     inhibitor. -   254. The method of any one of embodiments 177 to 247, wherein the     patient is postmenopausal. -   255. The method of embodiment 254, wherein the patient has locally     advanced or metastatic ER+/HER2- breast cancer. -   256. The method of embodiment 255, wherein the patient has     progressed on her first hormonal treatment while on a non-steroid     aromatase inhibitor (AI), fulvestrant, AI in combination with a     CDK4/6 inhibitor, or fulvestrant in combination with a CDK4/6     inhibitor.

6.6. Examples

Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

The practice of the present invention will employ, unless otherwise indicated, conventional methods of molecular biology, cell biology, biochemistry, genetics, cancer biology, and pharmacology, within the skill of the art. Such techniques are explained fully in the literature.

6.6.1. Example 1: Efficacy of Lasofoxifene on ESR1 LBD Mutations 6.6.1.1. Methods 6.6.1.1.1. Site-Directed Mutagenesis

ExSite mutagenesis was performed using the corresponding primers as summarized in Table 1 below on a pENTR2B ERα WT construct using Pfu ultra taq polymerase. The primers were PNK phosphorylated. Following PCR amplification, the products were digested with DpnI at 37° C. for 1 hr, followed by overnight ligation at 16° C. Ligated products were transformed into DH5α bacterial cells and grown on kanamycin resistant plates. The pENTR clones were verified by sequencing and then swapped into the pcDNA-DEST vector using the Gateway system (Invitrogen) for expression analysis.

TABLE 1 Primers for Mutagenesis ER Y537N For AATGACCTGCTGCTGGAGATG SEQ ID NO: 1 ER Y537N Rev GAGGGGCACCACGTTCTTGCA SEQ ID NO:2 ER Y537S For GACCTGCTGCTGGAGATGCTG SEQ ID NO: 3 ER Y537S Rev GCTGAGGGGCACCACGTTCTT SEQ ID NO:4 ER Y537C For TGTGACCTGCTGCTGGAGATG SEQ ID NO:5 ER Y537C Rev GCTGAGGGGCACCACGTTCTT SEQ ID NO: 6 ER D538G For GGTCTGCTGCTGGAGATGCTG SEQ ID NO: 7 ER D538G Rev ATAGAGGGGCACCACGTTCTT SEQ ID NO: 8

6.6.1.1.2. Cell Culture

Caov2 ovarian carcinoma cells were grown in RPMI-1640 media (Gibco) supplemented with 8% Fetal Bovine Serum (FBS), Sodium Pyruvate (NaPyr) and non-essential amino acids (NEAA) and passaged every 2-3 days. SKBR3 breast adenocarcinoma cells were grown in DMEM media (Gibco) supplemented with 8% Fetal Bovine Serum (FBS), Sodium Pyruvate (NaPyr) and non-essential amino acids (NEAA) and passaged every 2-3 days. Cells were switched into a phenol-red free RPMI-1640 media supplemented with 8% charcoal stripped fetal bovine serum (CFS), NaPyr, and NEAA one day before plating for experiment. Cells were then plated in 96-well plates for experiment in the phenol red-free media an additional day before transfection.

6.6.1.1.3. Reporter Gene Assay

Caov2 cells were co-transfected with the 7X-TK-ERE-TATA luciferase reporter gene (Nagel et al., Endocrinology 142(11): 4721-4728 (2001)) and expression constructs for either wild-type or mutant receptors using Fugene transfection reagent (Promega). SKBR3 cells were co-transfected with 3X-TK-ERE-TATA luciferase reporter gene in the same conditions. pCMV-β-gal was used as a control for transfection efficiency and pcDNA was added for a final DNA concentration of 75 ng per triplicate group. Cells were treated with indicated ligand five hours post transfection. Following 24 hours of treatment, cells were lysed and the luciferase and β-gal assays were performed as described previously (Norris et al., J Biol Chem 270(39): 22777-22782 (1995)) and the plates were read on the Fusion α-FP HT plate reader (PerkinElmer Life Sciences).

6.6.1.2. Results

ERα expression constructs were engineered to express one of four different ESR1 LBD mutations, Y537S, Y537N, Y537C, and D538G, which are found in metastatic breast cancer patients. See Jeselsohn et al., Nature Reviews Clinical Oncology 12(10): 573-583 (2015); Jeselsohn et al., Clinical Cancer Research 20(7): 1757-1767 (2014); Robinson et al., Nature Genetics 45(12): 1446-1451(2013); Thomas and Gustafsson, Trends in Endocrinology and Metabolism 26(9): 467-476 (2015); and Toy et al., Nature Genetics 45(12): 1439-1445 (2013). The activity of these mutants was evaluated in a reconstituted estrogen response element (ERE)-luciferase reporter assay in Caov2 ovarian carcinoma cells and SKBR3 breast adenocarcinoma cells. Data normalization is done in respect to the “0” data point (no ligand) of the wild-type receptor. As previously reported (Jeselsohn et al., 2014; Robinson et al., 2013; Toy et al., 2013), all of the mutants studied exhibited substantial constitutive activity when compared to the activity of wild-type (WT) ERα in the absence of its ligand: 17-β estradiol (E2). While the WT ERa responds to E2 in a dose-response matter, the transcriptional activity of the mutants is not responsive to E2 activation (FIG. 1A and FIG. 2A).

The ability of lasofoxifene to inhibit the transcriptional activity of the ERα mutants was next evaluated under the same conditions. All inhibition curves were done in the presence of 10⁻⁹ (1 nM) 17-β estradiol. Data normalization was done in respect to the “0” data point (no lasofoxifene) for each individual receptor. The plots include data from five independent experiments and each value is an average of triplicates from each experiment. Notably, lasofoxifene effectively inhibited the transcriptional activity of all tested ERα LBD mutants in a dose-response manner (FIG. 1B and FIG. 2B).

The transcriptional IC90 value of lasofoxifene was also evaluated under the same conditions in Caov2 ovarian carcinoma cells and SKBR3 breast adenocarcinoma cells. See Maximov et al., Current Clinical Pharmacology 8(2): 135-155 (2013). The transcriptional IC90 value of lasofoxifene evaluated was compared to the Cmax of these compounds in blood at doses used in prior clinical trials and approved in Europe. See Assessment Report for Fablyn, 2009 (EMA). The calculation included Cmax of lasofoxifene at theoretical doses of 0.5 mg and 1 mg. The additional dose of lasofoxifene (Img) was included to evaluate the potential clinical efficacy of lasofoxifene at a higher concentration. See Gardner et al., J Clin Pharmacol 46(1): 52-58 (2006). The results from Caov2 ovarian carcinoma cells and SKBR3 breast adenocarcinoma cells are summarized in Table 2.

TABLE 2 Comparison of IC90 Values to Reported Cmax Values WT Compound Reported Cmax Converted (M) Cmax Caov2 IC90 Caov2 Ratio Cmax/IC90 SKBR3 IC90 SKBR3 Ratio Cmax/IC90 Lasofoxifene (0.5 mg) 3.6 ng/mL 9.00E-09 6.68E-12 1346.8 3.30E-09 2.73 Lasofoxifene (1 mg) 6.43 ng/mL 1.55E-08 6.68E-12 2320.4 3.30E-09 4.69 Y537N Lasofoxifene (0.5 mg) 3.6 ng/mL 9.00E-09 7.45E-10 12.08 1.30E-08 0.69 Lasofoxifene (1 mg) 6.43 ng/mL 1.55E-08 7.45E-10 20.8 1.30E-08 1.19 Y537S Lasofoxifene (0.5 mg) 3.6 ng/mL 9.00E-09 1.22E-08 0.74 8.00E-09 1.13 Lasofoxifene (1 mg) 6.43 ng/mL 1.55E-08 1.22E-08 1.27 8.00E-09 1.94 Y537C Lasofoxifene (0.5 mg) 3.6 ng/mL 9.00E-09 2.04E-10 44.07 5.90E-09 1.53 Lasofoxifene (1 mg) 6.43 ng/mL 1.55E-08 2.04E-10 75.98 5.90E-09 2.63 D538G Lasofoxifene (0.5 mg) 3.6 ng/mL 9.00E-09 1.88E-09 4.80 7.10E-09 1.27 Lasofoxifene (1 mg) 6.43 ng/mL 1.55E-08 1.88E-09 8.24 7.10E-09 2.18

As expected, the WT receptor was the most responsive to anti-estrogen treatment, with each of the mutants exhibiting reduced response to the inhibitory actions of lasofoxifene. Importantly, the pharmacology of each of the mutants was different, which highlights the need to match patients with the most appropriate drug. The data suggest that lasofoxifene at a dose of 1 mg is most effective for patients whose tumors express the mutations in both ovarian and breast cancer settings.

6.6.2. Example 2: Efficacy of Lasofoxifene on ESR1 LBD Mutations Y537S and D538G in Stable Transfectants

MCF7 estrogen receptor alpha positive (ER⁺) breast cancer cells were engineered to stably express doxycycline (DOX)-inducible hemagglutinin (HA)-tagged full length ER with ligand binding domain mutations Y537S and D538G. The introduction and expression of the mutants were confirmed by Sanger sequencing, RNA-sequencing, and western blot.

The dose response studies were performed in full medium conditions. Cells were treated with DOX for the induction of HA-tagged mutated ER or with vehicle as control, and plated in triplicate. Subsequently, on day 5, cell counting was performed using the Celigo instrument with Hoechst dye staining to detect nucleated live cells and propidium iodide to quantify dead cells. Treatments included vehicle and increasing doses of lasofoxifene starting from 10⁻¹² M with 10 fold increments up to 10⁻⁶ M. The efficacy of the treatment is inversely proportional to the cell count.

The anti-estrogenic activity of lasofoxifene in a breast cancer model of ER mutations Y537S and D538G identified in Example 1 was confirmed by the ability of lasofoxifene to overcome resistance with increasing dose titration and kill the stably transfected cells (FIG. 3A and FIG. 3B).

IC50 values were calculated using PRISM. The results are summarized in Table 3.

TABLE 3 Comparison of IC50 Values in the Absence and the Presence of DOX Treatment Allele No DOX (wt only) DOX (ESR mutation) Fold Change Lasofoxifene Y537S 3.6E-10 4.1E-9 11.4 Lasofoxifene D538G 1E-10 1E-9 10

The results confirmed that lasofoxifene treatment is effective on the Y537S and D538G mutations, although the Y537S and D538G mutations require higher concentrations to overcome resistance.

6.6.3. Example 3: Lasofoxifene is Effective in a Mammary Intraductal (MIND) Xenograft Model of ERa⁺ Breast Cancer

MCF7 cells were engineered with CRISPR/Cas9 to express ERα with Y537S and D538G mutations. To mimic the natural environment of infiltrating ductal ERa⁺ breast cancers, NSG™ mice were injected, via the nipple in the inguinal mammary glands, with three MCF7 cell variants: wild type MCF7 cells (MCF7 WT), MCF7 cells expressing Y537S mutant ERα (MCF7 Y537S), and MCF7 cells expressing D538G mutant ERα (MCF7 D538G), respectively. Prior to injection, the MCF7 cells were labeled with a luciferase reporter to monitor tumor growth in vivo using a Xenogen IVIS imager. Mice were treated with vehicle five times per week, three different doses of lasofoxifene (1 mg/kg, 5 mg/kg, and 10 mg/kg) five times per week, or fulvestrant (5 mg; equivalent to 250 mg/kg in human) once per week, all by subcutaneous injection. FIG. 4 summarizes the experimental design.

Tumor growth was monitored by total flux over the course of treatment (FIGS. 8A-C, 9A-C, 10A-C, and 11A-C). In MCF7 WT mice, fulvestrant at 5 mg was the most effective in inhibiting tumor growth. In MCF7 Y537S or MCF7 D538G mice, tumor growth was most significantly inhibited by lasofoxifene at 10 mg/kg.

After 70 days of treatment, tumor growth was measured by tumor weight (FIGS. 12A-B). MCF7 Y537S and MCF7 D538G explant growth was significantly inhibited by 10 mg/kg lasofoxifene compared to the vehicle control. For the MCF7 Y537S explants, lasofoxifene significantly inhibited the growth of tumors at all tested doses. Compared to fulvestrant, lasofoxifene was significantly more effective at 5 mg/kg and 10 mg/kg for the MCF7 Y537S and MCF7 D538G tumors.

Liver and lung metastasis was measured after 70 days of treatment (FIGS. 13-19 ). Compared to fulvestrant, lasofoxifene at 5 mg/kg and 10 mg/kg was significantly more effective in reducing liver metastasis of the MCF7 Y537S explants. For the MCF7 D538G explants, lasofoxifene was effective in reducing liver metastasis at all tested doses (FIG. 15 ). Lasofoxifene at 5 mg/kg and 10 mg/kg significantly reduce lung metastasis for the MCF7 Y537S explants while fulvestrant did not have a significant effect (FIG. 19 ).

These data suggest that lasofoxifene inhibits tumor growth and metastasis of breast cancer in vivo in mouse models injected with breast cancer cells expressing D538G and Y537S mutant ERα. Importantly, lasofoxifene at doses of 5 mg/kg and 10 mg/kg is more effective than fulvestrant in reducing tumor growth and metastasis.

6.6.4. Example 4: Lasofoxifene Combined with Palbociclib is Effective in Inhibiting ERa Y537S Tumor Progression

MCF7 WT and MCF7 Y537S MIND xenograft model were generated as described in Example 3. Mice were treated with (a) vehicle five times per week via subcutaneous injection; (b) lasofoxifene at 10 mg/kg five times per week via subcutaneous injection; (c) fulvestrant at 5 mg/mouse (equivalent to 250 mg/kg in human) once per week via subcutaneous injection; (d) a CDK4/6 inhibitor, palbociclib, at 100 mg/kg five times per week via gavage; (e) the combination of lasofoxifene treatment at 10 mg/kg five times per week via subcutaneous injection plus palbociclib treatment at 100 mg/kg five times per week via gavage; or (f) the combination of fulvestrant treatment at 5 mg/mouse (equivalent to 250 mg/kg in human) once per week via subcutaneous injection plus palbociclib treatment at 100 mg/kg five times per week via gavage. FIG. 20 summarizes the experimental design.

Tumor growth was monitored by total flux over the course of treatment (FIGS. 21A and 21B). In MCF7 WT mice, fulvestrant alone was the most effective in inhibiting tumor growth. In MCF7 Y537S mice, tumor growth was most significantly inhibited by the combination therapy of lasofoxifene and palbociclib.

At day 36 and day 43 of treatment, tumor growth was determined by measuring the tumor volume (FIGS. 22A and 22B). Fulvestrant alone and the combination of fulvestrant and palbociclib were the most effective in inhibiting MCF7 WT tumor growth. The growth of MCF7 Y537S tumor was most inhibited by the combination of lasofoxifene and palbociclib.

6.6.5. Example 5: Lasofoxifene Inactivates the Constitutively Active Y537S ERa 6.6.5.1. Methods 6.6.5.1.1. Protein Expression and Purification

6x-His-TEV-Estrogen receptor alpha ligand binding domain containing C381S, C417S, C530S with L536S or Y537S mutations were expressed in E.coli BL21(DE3). The L536S mutant stabilizes the wild-type antagonist conformation and Y537S is an activating somatic mutation that has been identified in patients with acquired hormone resistance. Both proteins were purified using Ni-NTA resin, the 6x-His tag was cleaved using tev protease, removed using Ni-NTA resin, and a final purification was performed by passing the protein over a size exclusion column. The main peak was concentrated to 10 mg/mL and flash frozen.

6.6.5.1.2. Crystallization

The LBDs were incubated with 1 mM lasofoxifene for 4 hours at 4° C. Hanging drop vapor diffusion was used to crystallize the complexes. The L536S-Laso (lasofoxifene-bound ERα wild-type LBD) complex formed clear hexagonal crystals in 25% PEG 8,000, 200 mM MgCh, HEPES pH 7.5 after two weeks at room temperature. The Y537S-Laso (lasofoxifene-bound ERα Y537S mutant LBD) complex formed rectangular crystals in 20% PEG 3.35 K, 200 mM MgCh, HEPES pH 6.5 after one week at room temperature.

6.6.5.1.3. Data Collection and Refinement

Crystals were cryo-protected in 25% glycerol in mother liquor and flash frozen in liquid nitrogen. All x-ray crystallographic data sets were collected at the Advanced Photon Source. The L536S-Laso complex diffracted to 1.8 Å and the Y537S-Laso complex diffracted to 2.1 Å by cc^(½) over 50%. Phaser was used for molecular replacement with 5UFX as the model. Refinements were done using iterative rounds of Phenix Refine and Coot. The final R_(work)/R_(free) for the L536S-Laso was 22.05/26.09 and for the Y537S-Laso was 21.38/26.54.

6.6.5.2. Results

Similar to other SERMs, such as tamoxifen and raloxifene, lasofoxifene does not disrupt the loop between helix 11 and helix 12 in the ERα wild-type LBD crystal structure (FIG. 23A). In contrast, the loop between helix 11 and helix 12 is absent in the lasofoxifene-bound ERα Y537S mutant LBD crystal structure (FIG. 23B). Merge structures of lasofoxifene-bound ERα wild-type LBD and lasofoxifene-bound ERα Y537S mutant LBD also show the absence the loop between helix 11 and helix 12 in the lasofoxifene-bound ERα Y537S mutant LBD crystal structure (FIG. 24 ). Tamoxifen and raloxifene do not disrupt this loop in the ERα Y537S mutant LBD crystal structure.

Helix 12 plays a crucial role in determining interactions of ERα with coactivators and corepressors. The loop between helix 11 and helix 12 is important for placing helix 12 in the correct position in both on and off conformations of the estrogen receptor. The Y537S mutation imparts receptor activation independent of ligand binding. The x-ray crystal structure of the lasofoxifene-bound ERα Y537S mutant LBD shows that the binding of lasofoxifene to the ERα Y537S mutant lead to the disruption of the loop between helix 11 and helix 12, which can be sufficient to inactivate the constitutively active receptor.

The results are summarized in FIG. 25 . In the unbound wild-type ER, helix 12 is disordered and the co-activator binding groove (CBG) is not formed. The monomer ER is in the “off” state. When estrogen binds to the wild-type ER, helix 12 is stabilized and the CBG is fully formed. The binding also triggers the receptor dimerization. The dimerized ER is in the “on” state. ER ligand binding domain mutants, such as the Y537S mutant, mimic the conformation of the estrogen-bound wild-type receptor. When lasofoxifene binds to the Y537S mutant, it occupies the ligand binding pocket (LBP). The loop between helix 11 and helix 12 is displaced and helix 12 is shifted to block the CBG. The lasofoxifene-bound Y537 mutant is in the “off” state.

6.6.6. Example 6: Phase 2 Clinical Study

A phase 2 clinical study is conducted to evaluate the efficacy of lasofoxifene in postmenopausal women with ER⁺HER2⁻ advanced or metastatic breast cancer.

6.6.6.1. Study Design

The design of the study is outlined in FIG. 26 . The study is an open label, randomized, multicenter study. Full recruitment into study occurs within twelve to sixteen months, with another twelve months of follow up before the primary outcome measure is analyzed. Screening tests are performed within thirty days of enrollment. Subjects are treated until documented disease progression.

6.6.6.2. Drug Schedules

Lasofoxifene is given to the breast cancer patient at 5 mg once daily by oral administration. As a comparison, fulvestrant is given to the breast cancer patient at 500 mg by intramuscular injection on day 1, day 15, and day 29, and then once every month.

6.6.6.3. Primary and Secondary Endpoints

The primary endpoint is the progression free survival (PFS) of 5 mg lasofoxifene treatment relative to fulvestrant treatment.

The secondary endpoints include: clinical benefit rate (CBR), duration of response, objective response rate (ORR), quality of life (QoL), safety of lasofoxifene, and time to response.

6.6.6.4. Inclusion and Exclusion Criteria

The inclusion criteria include:

-   1. Postmenopausal women with: a. locally advanced or metastatic     breast cancer with either measurable or non-measurable lesions, b.     progression on an AI in combination with a CDK 4/6 inhibitor for     advanced breast cancer; -   2. If possible, a biopsy of metastatic breast cancer tissue will be     obtained to confirm ER⁺ and HER2 disease; -   3. At least one or more of the following ESR1 mutations: Y537S,     Y537N, Y537C, D538G, L536, E380Q, or S463P assessed from tumor-free     DNA in blood; -   4. Received one chemotherapy regimen in the neo-adjuvant or adjuvant     setting prior to entry into the trial; -   5. ECOG performance score of 0 or 1.

Subjects who meet any of the following criteria will be excluded from entering the trial:

-   1. Prior use of any SERM in the adjuvant or metastatic setting; -   2. Presence of brain metastasis or lymphangitic carcinomatosis     involving the lung; -   3. Impending visceral crisis as assessed by the investigator; -   4. Radiotherapy within 30 days prior to randomization; -   5. History of long QTc syndrome or a QTc of >480 ms; -   6. History of a pulmonary embolus (PE) or deep vein thrombosis (DVT)     within the last 6 months, or any known thrombophilia; -   7. History of a positive human immunodeficiency virus (HIV),     hepatitis B virus (HBV) or hepatitis C virus (HCV) at screening.

6.6.6.5. Visit Schedule

Vital signs, height, weight, physical exam, and adverse event (AE) assessment are measured at each visit. If the patient has metastatic bone lesions at baseline, a bone scan is performed every two months. An MRI or CT of the chest, abdomen and pelvis is performed every two months or sooner if clinically indicated. A CBC with differential, routine chemistries, and sample for PK analysis are determined at each visit.

6.6.6.6. Statistical Analysis

The progression free survival (PFS) is compared between the lasofoxifene and fulvestrant arms using the stratified log-rank test. Median PFS for each treatment arm are estimated by the Kaplan-Meier method and the lasofoxifene over fulvestrant hazard ratio are estimated by the Cox proportional hazards model.

6.6.6.7. Results

Lasofoxifene increases the median PFS compared to fulvestrant in the ESR1 mutation population.

Lasofoxifene increases the median PFS compared to fulvestrant in the Y537S mutant patient population. Lasofoxifene increases the median PFS compared to fulvestrant in the Y537N mutant patient population. Lasofoxifene increases the median PFS compared to fulvestrant in the Y537C mutant patient population. Lasofoxifene increases the median PFS compared to fulvestrant in the D538G mutant patient population. Lasofoxifene increases the median PFS compared to fulvestrant in the L536 mutant patient population. Lasofoxifene increases the median PFS compared to fulvestrant in the E380Q mutant patient population. Lasofoxifene increases the median PFS compared to fulvestrant in the S463P mutant patient population.

7. EQUIVALENTS AND INCORPORATION BY REFERENCE

While the invention has been particularly shown and described with reference to a preferred embodiment and various alternate embodiments, it will be understood by persons skilled in the relevant art that various changes in form and details can be made therein without departing from the spirit and scope of the invention.

All references, issued patents and patent applications cited within the body of the instant specification are hereby incorporated by reference in their entirety, for all purposes. 

1-256. (canceled)
 257. A method of reducing progression of estrogen receptor positive (ER⁺) ovarian cancer in a patient, wherein the cancer has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene, the method comprising: administering to the patient an effective amount of lasofoxifene or a pharmaceutically acceptable salt thereof.
 258. The method of claim 257, wherein the cancer has previously been determined to have at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene.
 259. The method of claim 257, further comprising the earlier step of: determining that the cancer has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene.
 260. The method of claim 257, wherein the at least one of gain of function missense mutation is in any one of amino acids D538, Y537, L536, P535, V534, S463, V392, and E380 of the ERα protein.
 261. The method of claim 260, wherein the at least one of gain of function missense mutation is D538G, Y537S, Y537N, Y537C, Y537Q, L536R, L536Q, P535H, V534E, S463P, V392I, or E380Q.
 262. The method of claim 260, wherein the at least one of gain of function missense mutation is in amino acid D538 or Y537 of the ERα protein.
 263. The method of claim 262, wherein the at least one of gain of function missense mutation is D538G, Y537S, Y537N, Y537C, or Y537Q.
 264. The method of claim 257, wherein the patient has previously been treated with one or more lines of endocrine therapy.
 265. The method of claim 264, wherein the endocrine therapy that the patient has previously been treated with is a selective ER modulator (SERM) other than lasofoxifene, a selective ER degrader (SERD), or an aromatase inhibitor (AI).
 266. The method of claim 265, wherein the endocrine therapy that the patient has previously been treated with is an aromatase inhibitor.
 267. The method of claim 266, wherein the aromatase inhibitor is exemestane, letrozole, or anastrozole.
 268. The method of claim 264, wherein the patient has had disease progression after endocrine therapy.
 269. The method of claim 257, wherein the patient is postmenopausal.
 270. The method of claim 257, wherein lasofoxifene is administered as lasofoxifene tartrate.
 271. The method of claim 257, wherein lasofoxifene is administered by oral administration.
 272. The method of claim 271, wherein lasofoxifene is administered orally at 5 mg/day.
 273. The method of claim 257, further comprising administering to the patient an effective amount of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
 274. The method of claim 273, wherein the CDK4/6 inhibitor is abemaciclib.
 275. The method of claim 273, wherein the CDK4/6 inhibitor is palbociclib.
 276. The method of claim 280, wherein the CDK4/6 inhibitor is ribociclib.
 277. The method of claim 257, wherein the ovarian cancer is locally advanced or metastatic.
 278. A method of reducing metastasis of estrogen receptor positive (ER⁺) ovarian cancer in a patient, wherein the cancer has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene, the method comprising: administering to the patient an effective amount of lasofoxifene or a pharmaceutically acceptable salt thereof. 